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Chemical Mutagenesis for the Modulation and 
Study of Protein Function and Dysfunction within 
Alzheimer’s Disease 
Philip Richard Lindstedt 
Abstract 
Chemical mutagenesis is defined as the post-expression interconversion of amino-acid (AA) 
sidechains. This approach enabled the first ever point-mutations in proteins and has seen a 
resurgence of interest over the last two decades. This thesis reports on two disparate 
applications of chemical mutagenesis within the context of Alzheimer’s disease (AD). First, 
exploring the capabilities of utilizing chemical mutagenesis to enable a structure-activity 
relationship study on a single-domain antibody (SdAb) beyond the 20 canonical AAs. The 
starting SdAb was designed to target the Amyloid-b	peptide (Ab) and has a nascent ability to 
inhibit its aggregation, a key pathological process in AD. Utilizing the synthetically versatile 
non-canonical AA dehydroalanine (Dha), we explore diverse sidechains at key residues along 
the binding loop of the SdAb and identify a non-canonical sidechain that potently enhances 
the inhibition of Ab’s primary nucleation. The second application focuses on the other major 
protein implicated in the pathology of AD: Tau. In AD, tau aggregates into ordered amyloid 
fibrils and contains a plethora of post-translational modifications (PTMs), many of which are 
speculated to have an impact on the pathogenesis of AD as well as other so-called 
tauopathies. In order to facilitate the accurate study of tau PTMs, an easily accessible method 
for their site- selective installation is needed. To this end, we again explore the utilisation of 
Dha to install accurate PTM mimetics for phosphorylation, lysine acetylation, and lysine 
dimethylation at diverse sites along tau. This approach produced homogenous products that 
accurately recapitulated known behaviours and allowed for the initial characterisation of 
poorly investigated PTMs. The characterisation of S199 phosphorylation, a known AD 
associated modification, through this approach provides the first evidence for its potential 
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Chapter 1: Introduction  
 
1.1 Protein aggregation and disease  
 
1.1.1. Protein folding   
 
 At the most fundamental level, the main requirement for the propagation of living 
systems is its components’ ability to reliably self-assemble. From this deceivingly simple 
capability, life is able to build the complex systems necessary for everything from metabolism, 
to replication, and all of the other intricate functions leading to the great diversity that life has 
achieved. Essential to the self-assembly required for life is the ability of proteins to fold into 
their native three-dimensional structure1. It is hard to overstate how profound it is that proteins 
can, by and large, fold on their own incredibly rapidly (on the order of µs-ms)2. While native 
states almost always correspond to the most stable structure of a protein under physiological 
conditions3, within the cell proteins are generated as a linear polypeptide from the exit tunnel 
of the ribosome. In the case of the small 110 residue protein Barnase, from estimates of main-
chain entropy per residue, the number of conformations per residue in this initial random-coil 
state was calculated to be 2.57, when extended to the whole protein that becomes 2.57109 
(~1044) number of states4. A random search through this conformational space to the native 
state would take much longer than the lifetime of the universe. This observation is famously 
known as Leventhal’s paradox4. From observations such as this, it became clear that the folding 
of proteins, at least for those capable of spontaneously folding, is largely encoded by its amino 
acid sequence. Through the implementation of a myriad of experimental and theoretical 
techniques, it became clear that within the sequence of proteins was encoded a free-energy 
landscape to guide the folding of the protein5 (Figure 1.1a). The landscape is shaped by the 
fact that, on average, native-like interactions between residues are more stable than aberrant 
interactions, and once a critical few interactions have been made to create a folding nucleus, 
then the remaining structure rapidly condenses into the native state6. This is at least the case 






a         b          c 
 
Figure 1.1. Protein folding and the amyloid state. (a) The averaged effective energy surface 
of the folding of lysozyme based on experimental data with three folding trajectories: fast 
folding (yellow), slow folding crossing a high energy barrier (green), and a slow folding state 
that returns to a less folded state before following the fast folding trajectory (red). E represents 
the free energy, P is a measure of the conformational space, and Q is the number of native 
contacts. (b) Illustration depicting the stability of amyloid fibrils and their intermediate 
aggregate’s free energy compared to the native state and a possible point of intervention 
molecular chaperones can take to inhibit the process. (c) TEM image of the amyloid fibrils 
from an 11-residue peptide (left) and close-up view of the magic-angle spin NMR atomic 
resolution structure of the fibrils (centre/right). Figures modified with permission from 
references [2], [8], and [10], respectively.  
 
1.1.2. The amyloid state   
 
 While the amino acid sequence of proteins can guide the folding process, there are 
many perturbations in vivo that can either interfere with the initial folding or cause partial or 
complete unfolding of a protein7. Functionally compromised proteins are closely monitored by 
a proteostasis system that is highly conserved through all domains of life8. Within this system, 
there are a plethora of entities that either assist with the initial folding, refolding, or degradation 
of irrevocably lost proteins. One increasingly recognised function of this system is the 
inhibition of the amyloid state, an intractable and highly stable protein structure9. (Figure 
1.1b).   
 Interestingly, regardless of the protein or peptide of origin, amyloid structures share 
many similar traits. This state is characterised by the formation of long (often micron-length) 
fibrils possessing a cross-b structure where the b-strands are oriented perpendicular to the fibril 
axis10 (Figure 1.1c). Remarkably, once adopted by a protein, the amyloid state can be even 
more thermodynamically favourable than the native state (Figure 1.1b). In contrast to how the 
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native state of a protein is largely coded in its amino-acid sequence, there are many 
observations that suggest that the amyloid state is an innate structure all polypeptides can adopt. 
This hypothesis was inspired by observations that conditions could be found for almost any 
normally globular protein to convert to amyloid fibrils. An initial striking demonstration of this 
was with muscle myoglobin by Fandrich and co-workers11. In its native state, muscle 
myoglobin is a highly soluble and a-helical rich protein, and all of its partially folded states 
are also predominantly a-helical12. However, the researchers found that if the apo form of the 
protein (lacking haem) was incubated in 50 mM sodium borate buffer, pH 9.0 and at 65 °C, it 
resulted in the deposition of long ordered fibrillar structures with the characteristic signatures 
of a cross-b structure by X-ray diffraction and FTIR. The identification of conditions for the 
conversion of numerous other normally soluble proteins into amyloid fibrils supports this 
observation13-15. However, perhaps most convincing of the theory of universal amyloid 
formation is the ability of single amino acids to form the structure. In a seminal study by Adler-
Abramovich and co-workers, the pathological deposition of amino acid L-phenylalanine was 
studied in detail in the context of the disease phenylketonuria (PKU)16. PKU is an autosomal 
recessive disorder causing an inability to metabolise L-phenylalanine, leading to the 
accumulation of L-phenylalanine to millimolar levels throughout several body tissues, 
including the brain17. The researchers found that under physiological conditions in vitro this 
high concentration leads to the deposition of highly ordered supramolecular assemblies with 
all of the hallmarks of amyloid fibrils mentioned previously. How is it possible that so many 
disparate sequences can adopt this structure? While in the native state side-chain interactions 
are the key players in defining the main-chain fold, it has become clear that the amyloid 
structure is driven by main-chain interactions that are common to all polypeptides. Indeed, it 
has been shown that it is the longitudinal backbone hydrogen bonding network along the fibril 
axis that is the main contributor to the stability of these structures18. However, the kinetic 
barriers to accessing the amyloid state are heavily influenced by the amino acid sequence and 
conditions.  
These examples of aberrant amyloid formation by natural protein sequences and 
peptides led many to believe that nature had evolved to select for sequences, conditions and 
systems to suppress the formation of this universal structure. However, nature has a remarkable 
ability to utilise even extreme physiochemical phenomena. It is now clear that functional 
amyloids are pervasive through all domains of life19. Within mammals, this is exemplified by 
the protein Pmel17, which is responsible for the polymerisation of melanin20. Fowler and co-
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workers demonstrated through histochemistry that mammalian melanosomes contain a 
significant level of amyloid, suspected to arise from Pmel17 through genetic studies21,22. 
Indeed, when Pmel17 was recombinantly expressed and isolated it was then found to form 
amyloid fibrils at a remarkable rate (rate-limited by the experimental apparatus). The function 
of the amyloid nature of Pmel17 is believed to be as a scaffold to template the polymerisation 
of melanin and sequester the reactive and toxic melanin precursors from the cellular milieu. 
While the utilisation of the amyloid fold for cellular activity was a paradigm shift in the protein 
misfolding field, it is now established that that these functional amyloids have a multitude of 
features that have evolved to avoid the more malicious traits of these structures.  
 
1.1.3. Pathological protein misfolding    
  
As alluded to in the above section, amyloid formation has most famously been 
associated with disease processes. Protein misfolding can bring about disease through two 
broad mechanisms: loss of function or gain of toxicity. In the loss of function mechanism, 
impaired folding results in either enhanced degradation or improper trafficking of the protein, 
leading to a reduction of the level of functional protein to perform its normal role. This is the 
case in diseases like cystic fibrosis and early onset emphysema23,24. The majority of protein 
misfolding diseases, however, fall into the gain of toxicity category. Over the last several 
decades thirty-seven proteins and peptides have been found to form amyloid structures in a 
variety of human maladies (see Table 1.1 for examples)25. The symptomatic manifestations of 
these diseases vary widely, from dementia, to diabetes, to cardiomyopathy, and depend entirely 














peptide/protein Number of residues Associated diseases Native structure 
Neurodegenerative diseases 
Amyloid-β 40 or 42 Alzheimer’s disease Intrinsically disordered 
Tau 352 - 441 










Parkinson’s disease with 
dementia, dementia with 











All-β, prealbumin like 
Huntington exon 1 
(HttEx1)  103-187 Huntington disease Intrinsically disordered 
Non-neuropathic systemic amyloidosis  
Immunoglobulin (Ig) light 
chains or fragments thereof  ~100 Light-chain amyloidosis  All-β, Ig like 
Lysozyme 130 Lysozyme amyloidosis  𝛼 and β, lysozyme fold 
β2-microglobulin  99 
Dialysis related 
amyloidosis  All-β, Ig like 
Non-neuropathic localised amyloidosis  
Islet amyloid peptide 37 Type-II diabetes, insulinoma Intrinsically disordered 
Medin 50 Aortic medial amyloidosis  Intrinsically disordered 
Galectin 7 136 Lichen amyloidosis, macular amyloidosis 
All-β, concanavalin A-like 
lectins 
Pulmonary surfactant- 






Table 1.1. Examples of human diseases associated with amyloid aggregation.  
 
Genetic studies of this disparate class of diseases reveal interesting insights into the 
perturbations that can lead to amyloidopathies (Figure 1.2). From gene duplication or 
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expansion, to RNA splicing alterations, to structural destabilisation, these types of studies have 
revealed that amyloidopathies can arise from mutations that cause malfunctions at every stage 
of the genesis and life of a protein. For large errors in the DNA replicative machinery, one of 
the most well studied cases is with the duplication and triplication of the a-synuclein gene 
(SNCA) in certain cases of familial Parkinson’s disease. One of the hallmarks of Parkinson’s 
disease is the deposition of amyloid plaques of the protein a-synuclein, leading to a progressive 
loss of dopaminergic neurons26. Triplication of the SNCA gene was observed in a Swedish-
American family and resulted in an autosomal dominate early-onset form of Parkinson’s with 
Lewy body dementia27. In contrast, duplication of the SNCA gene in a French family led to an 
autosomal dominant form of the disease but with a progression pattern resembling idiopathic 
forms and no cognitive impairments28. Analysis of the increased mRNA and soluble protein 
concentrations of brain tissues from these families revealed that an increase of SNCA gene 
copies dose dependently increases the expression of a-synuclein27. This correlation between 
expression of the amyloidogenic protein and disease severity is indicative of how errors in the 
larger replicative machinery at the DNA level can induce or exacerbate amyloidopathies. More 
subtle genetic alterations can also lead to the onset of amyloidopathies. This is the case for one 
of the most thoroughly studied misfolding diseases: Transthyretin amyloid disease. Normally, 
transthyretin is found in human serum as a stable homo-tetramer functioning as a transporter 
for thyroxine and retinol. More than 80-point mutations have been identified within the 
transthyretin gene that lead to the pathogenetic deposition of the amyloid form of the protein, 
invariably ending in fatal complications29. Through many biophysical studies, the root-cause 
of amyloid formation from these mutations was determined to be the destabilisation of the 
tetramer structure30-33. The dissociated monomer has a greatly diminished kinetic barrier to 
adopting the amyloid state compared to higher ordered forms, and the shift in binding 
equilibrium brought about by these point-mutations is enough to produce a critical 
concentration of unstable monomer to initiate amyloid formation. Unique to transthyretin 
amyloid disease, these thorough mechanistic studies did more than elucidate its aetiology, they 
laid the foundation to guide a therapeutic approach. Kelly and co-workers used the knowledge 
of the destabilisation of the tetramer to screen for small-molecule stabilisers of the pathogenic 
mutations30. This work has culminated with the first disease modifying therapy of a protein 
misfolding disease on the market that has gone on to save thousands of lives already34.  
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Figure 1.2. Mechanisms of action by which genetic alterations cause protein misfolding. 
Numbers 1-10 show different examples of aggregating proteins and the genetic alterations that 
encourage their misfolding.  
1 Duplication, triplication or expansion of a gene 
coding for a protein predisposed to aggregation can 
lead to higher concentrations of the protein or 
extend amyloidogenic regions (!S, Aβ, HttEx1)
2 Mutations causing influencing splicing events, 
causing the expression of proteins with more of an 
amyloidogenic sequence (Tau)  
3 Mutations leading to premature 
termination of translation, causing the 
production of unfolded fragments (PrP) 
4 Genetic alterations causing late 
termination of translation, leading to 
the addition of amyloidogenic or 
unfolded regions ( ABri, ApoAII) 
Unfolded protein
Proteolysis 
5 Mutations altering 
proteolysis sites, forming 
aggregation prone 
fragments (Aβ)
6 Mutations increasing the 
aggregation rate of 
proteins (Aβ, Tau, !S) Amyloid aggregates
Partially folded 
structure
7 Mutations that destabilize the native structure, 
causing amyloidogenic sequences to be 
exposed and promoting aggregation (TTR,PrP) 
8 Destabilizing mutations that encourage 
proteolysis and the generation of 
amyloidogenic fragments (ApoAI) 
9 Mutations 
destabilizing 
binding to partner 
proteins (Tau)
10 Mutations altering affinities for stabilizing 









While these genetic alterations explain how amyloid formation can be spurred, how do 
amyloid structures themselves cause disease? In the early days of the protein misfolding field, 
the pathological culprit was thought to be the amyloid fibrils themselves. In certain non-
neurological amyloidopathies this is indeed the case, where kilograms of fibrils can be 
deposited, thereby leading to organ dysfunction35. However, for the majority of protein 
misfolding diseases, this turned out to be an overly simplistic and incomplete explanation for 
the pathogenicity of these structures. Over the decades it has become clear that most of these 
diseases have a very multifaceted mode of toxicity, interacting with a wide array of cellular 
and physiological systems. For the toxicity directly associated with misfolded proteins, it is 
increasingly accepted that the primary pathogenic species are the on-pathway oligomers that 
are generated throughout the aggregation process. This mechanism was initially hypothesised 
upon the observation that early stage non-fibrillar aggregates exhibited substantial toxicity to 
cultured cells, while fully fibrillar species were harmless (Figure 1.3a)36. Further insight was 
gleaned from this particular study because the proteins investigated were not disease 
associated; they were normally globular proteins that only form amyloid structures under the 
appropriate in vitro conditions, and yet, their on-pathway aggregates still were highly toxic, 
implying that oligomer mediated cell death is a potentially universal mechanism of toxicity 
across amyloidopathies. This hypothesis has been supported through a multitude of clinical 
observations37-39. For example, in transthyretin misfolding disease the onset of symptoms 
corelates with the deposition of the protein in a non-fibrillar form histologically distinct from 
later stage amyloid structures40. Follow up in vitro studies confirmed that low mass (<100 kDa) 
assemblies were the most cytotoxic species in the transthyretin aggregation process41.  
Oligomer mediated cell-death has been determined to largely arise through non-specific 
membrane disruption. The physiochemical characteristics of oligomers facilitating this 
disruption has been well characterised using the model protein HypF-N. HypF-N is an E. coli 
derived protein that is particularly well suited to this type of mechanistic study, this is because 
HypF-N can readily form an array of pre-fibrillar species that persist long enough to enable 
their study, unlike the typical highly transient species in other misfolding pathways42. In 
particular, conditions were found to produce two distinct types of stable oligomers with 
drastically different toxicities (Figure 1.3b)43. Initial characterisation of the two oligomer 
forms, toxic and benign, through typical tinctorial tests and atomic force microscopy (AFM) 
revealed very similar morphologies between the two. To perform a more in-depth investigation 
of the oligomer structures, a panel of 18 single cysteine mutants of the protein were expressed 
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and labelled with N-(1-pyrene)maleimide (PM). PM acts as a probe for proximity, because 
when two PM groups are within 10 Å of each other they form exited-state dimers, giving rise 
to a new fluorescence emission in the 430-470 nm region. This facilitated the investigation of 
the packing of the core of the oligomers, which revealed that in the toxic variant the core is 
much less tightly packed, and that the hydrophobic residues that are buried in the native 
structure and in the non-toxic oligomers are exposed on the surface. This was corroborated by 
measuring the binding of the different oligomers to the dye 8-anilinonaphthalene-sulfonate 
(ANS), which experiences a marked increase in fluorescence upon interacting with solvent-
exposed hydrophobic clusters. This surface exposed hydrophobicity of oligomers appears to 
be the key characteristic that enables membrane disruption. Further structure-toxicity related 
studies of HypF-N oligomers have elucidated that, along with increased surface 
hydrophobicity, the toxicity of oligomers is inversely proportional to their size (Figure 1.3c)44. 
Supporting this general mechanism for misfolding diseases, nuclear magnetic resonance 
(NMR) studies of a-synuclein oligomers of various toxicities has elucidated the exact 
lipophilic structures that need to be present to mediate membrane disruption45. Taken 
altogether, these genetic and biophysical studies of protein misfolding over the last several 
decades have begun to create a wholistic picture of the pathogenic processes behind this diverse 
class of diseases.  
 
 
Figure 1.3. Toxicity of on-pathway oligomeric species. (a) Comparison of the toxicities of 
fibrillar aggregates (above) and granular (oligomeric, below) aggregates of the SH3 domain of 
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bovine PI3-kinase measured by MTT reduction. (b) Schematic representations of the structural 
differences of toxic (type A, red) HypF-N oligomers and non-toxic ones (type B, blue). Surface 
exposed hydrophobic side chains are highlighted in yellow. Structures were determined using 
a variety of biophysical techniques. (c) 3D plot displaying MTT reduction values (toxicity, z-
axis), ANS lmax (hydrophobicity, x-axis), and Rayleigh ratio (size, y-axis) of 12 different 
oligomeric variants of HypF-N. Figures modified with permission from references [36], [44], 
and [45], respectively. 
 
1.1.4. Alzheimer’s disease: The amyloid-ß peptide  
 
Protein misfolding diseases are most prevalent in neurodegenerative disorders, in 
particular dementias, and none more famously than Alzheimer’s disease (AD). Indeed, AD is 
poised to become a plague in the 21st century, with predictions that more than 140 million 
people will be afflicted with the disease by 205046. AD, along with Parkinson’s disease (PD), 
is typically a sporadic disease with no clear cause of onset. Although there are hereditary forms 
of the disease that shed some insight into its aetiology. However, the greatest risk factor by far 
for the disease is age, hence the predicted dramatic rise of cases in the 21st century due to the 
increasingly aged population of developed countries.   
a      b 
  
Figure 1.4. Ab production. (a) Illustration of the amyloidogenic and anti-myloidogenic 
pathways of APP processing. (b) Cleavage sites of presenilin leading towards the Ab40 and 
Ab42 product lines and the preceding epsilon cleavage sites.  
 
Post-mortem, the brain tissue of AD patients is characterised by the presence of two 
different proteinaceous inclusions: extracellular amyloid plaques and intracellular 
neurofibrillary tangles (NFTs)47. The morphological differences of these structures also reflect 
unique compositions, the former is largely composed of truncated peptides derived from the 
amyloid precursor protein (APP), predominately the Ab42 peptide, and the latter are formed by 
the microtubule associated protein tau. While both of these structures contribute to the disease 
progression of Alzheimer’s, there is considerable evidence that the accumulation of Ab42, and 
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related peptides, is the beginning of the pathogenic cascade. A major observation supporting 
this is that all dominant mutations that lead to AD are either in the APP gene, or in the proteases 
that processes APP48. APP is a highly conserved type-1 transmembrane protein 
(luminal/extracellular amino terminus and cytosolic carboxy terminus) with a largely unknown 
primary function. While it is expressed in many tissues, it is found at the highest levels in 
neurons49. APP is processed by a succession of different proteases that can be classified into 
two main pathways: the amyloidogenic pathway and anti-myloidogenic pathway (Figure 
1.4a). The two paths begin their divergence when the initial cleavage is carried out by a or ß-
secretase. a-Secretase will cleave approximately in the middle of the Ab region of APP, 
thereby avoiding the production of pathological species altogether, while the b-secretase 
(BACE1) cleaves deeper into the luminal domain, opening up the possibility of the production 
of highly amyloidogenic peptides50. The final release of the amyloidogenic peptides from the 
b-processed fragment (CTFb) is then mediated by the g-secretase, which is a complex 
consisting of 4 subunits, with the catalytic unit being the membrane-embedded aspartyl 
protease presenilin51. Presenilin processes CTFb in a complex stepwise cleavage mechanism 
within the transmembrane domain (Figure 1.4b). Akin to the initial two paths between the a 
or b-secretases, depending on the first (also termed e) cleavage by presenilin, CTFb can either 
take the Ab40 (less pathogenic) or Ab42 (more pathogenic) product pathway52. The reasons for 
the variable activity of presenilin are not well understood, but what is clear is that mutations 
within the protease that favour Ab42 production are AD-associated53. Likewise, mutations 
within the APP gene that favour different cleavage patterns also lead to hereditary forms of 
AD, like the so-called Swedish mutation that creates a better substrate for the initial b-
secretase, causing a significant increase in total Ab production54. Additionally, there are also a 
wide range of mutations within Ab that enhance its propensity to aggregate leading to 
hereditary forms of AD50.    
Regardless of how Ab is produced, once it is allowed to accumulate to critical levels it 
will begin to oligomerise, initiating a complex cascade affecting many systems within the 
brain. Similar to other protein misfolding diseases, the oligomers of Ab display toxicity and 
lead to significant levels of neuronal death themselves55. In particular, there is growing 
evidence that intracellular oligomer formation within the ER is particularly damaging to cells. 
This has been elegantly proven by Cattaneo and co-workers through the implementation of ER 
localised intrabodies that disrupt this pathway of Ab aggregation56,57. They were able to 
demonstrate that these intrabodies ameliorated the defects of neurons isolated from Tg2576 
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transgenic mice, a common animal model of AD57. Besides their innate toxicity, it has become 
clear that Ab oligomers, and other higher ordered species up to fibrils, cause further 
perturbations in the brain exacerbating the damage. Perhaps most significantly, these 
extracellular Ab species lead to the onset of significant neuroinflammation through the brain’s 
innate immune system. Beginning with microglia, the brain resident macrophage, Ab 
oligomers have proven to induce a potent inflammatory response, releasing a plethora of 
cytokines that recruit and polarise other microglia into a neurotoxic state as well as astrocytes, 
glial cells responsible for maintaining the extracellular environment of the brain58. While there 
are many events that take place during Ab mediated neuroinflammation, the most 
consequential appears to be the microglia/astrocyte mediated activation of the complement 
system (Figure 1.5). During development, the complement system is activated in the brain to 
prune excess synapses by microglial mediated phagocytosis and is necessary for proper 
maturation of the nervous system59. Hong and co-workers hypothesised that this system was 
being inappropriately activated during AD, leading to the synaptic loss that is strongly 
correlated with cognitive decline60. To investigate this, they studied the dynamics of synapse 
loss in J20 transgenic mice. This mouse strain has been developed to overexpress human APP 
with the aforementioned Swedish mutation, elevating the production of CTFb, and the Indiana 
mutation, favouring the Aß42 cleavage pathway by presenilin61. Using advanced super-
resolution microscopy techniques, the team was able to show that in the synapses in the 
hippocampal and frontal cortex regions of AD mice were significantly more associated with 
the protein C1q, the initiating protein of the classical complement cascade (Figure 1.5). By 
using compounds that inhibit the g-secretase complex, and therefore Ab production, and 
studying the effects of localized injections of either Ab oligomers or monomers into the brain, 
the researchers were able to show that synaptic targeting by C1q was enhanced by the presence 
of Ab oligomers specifically. This complement mediated loss of synapses was also observed 
well before the deposition of plaques, an important observation from a therapeutic perspective 
since it supports the belief that early pre-plaque intervention is necessary to effectively combat 
AD62.  Alongside other studies that have demonstrated that Ab activated microglia further 
exacerbate the activation of the complement system by inducing astrocytes to produce the 
protein C363, the mediator of the alternative complement pathway, it is clear that on top of the 
inherent toxicity of Ab aggregation, in AD Ab has many avenues to initiate synaptic loss. 
However, the route to cell death, the hypothesis that elevated Ab accumulation is ultimately 
the initiating factor leading the AD pathogenesis is becoming progressively more supported 
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despite doubts due to the failure of therapeutic interventions based on this hypothesis. Some of 
the reasons for these failures will be discussed in later sections.  
 
 
Figure 1.5. Complement system in AD. Illustration of the consequences arising from the mis-
activation of the complement system in the brain during Alzheimer’s disease triggered in 
response to Ab oligomers. Through yet to be determined signals (represented by the red X), 
astrocytes can induce neurons to produce C1q themselves (yellow symbols). C1q is also created 
by reactive microglia. Opsonisation by C1q then encourages the cleavage of C3 into its active 
form C3b, which then further encourages synaptic phagocytosis through the alternative 
complement pathway.  
 
1.1.4. Alzheimer’s disease: Tau  
 
 Besides Ab, the other major protein forming amyloid structures in AD is the protein 
tau. Unlike APP, tau has a well-known physiological role. Under normal conditions tau is 
predominantly expressed in neurons of the central nervous system, where it primarily stabilises 
neuronal microtubules (MTs) to promote axonal outgrowth64. Tau can be divided into three 
major domains, the C-terminal assembly domain responsible for MT binding, a proline-rich 
domain, and the N-terminal projection domain (Figure 1.6a). There are 6 main splice variants 
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of tau protein in the brain based on the inclusion or exclusion of different subdomains, all 
expressed from the MAPT gene, with the longest isoform being the 2N4R form at 441 amino 
acids. In this nomenclature, the 2N refers to the inclusion of two near-amino-terminal inserts 
and the 4R refers to the presence of 4 repeat domains within the MT binding domain, where 
only the second repeat is the varied domain (Figure 1.6a). Regardless of splicing, NMR and 
small-angle X-ray scattering studies have shown that tau is an intrinsically disordered protein 
in the absence of a binding partner65. Early studies of tau also found that it has a very low 
propensity to aggregate in vitro and established that it is an unusually hydrophilic protein with 
many polar or charged side-chains64. Therefore, the ability for tau to form well-ordered fibrillar 
structures in vivo appears to be a peculiar phenomenon. This peculiarity is further accentuated 
by the fact that fibrillar tau deposits are not only observed in AD, but in a whole family of 
neurodegenerative diseases termed tauopathies66.  While some tauopathies have amyloid 
deposits consisting of all isoforms, such as AD, some diseases, like Pick’s disease, only have 
a subset of the isoforms comprising the deposits67. From these observations, it is clear that 
some potentially very specific mechanisms regulating tau behaviour become dysfunctional in 
these disease processes.  
 Studies of the structures of tau deposits help to shed some light on how this seemingly 
stable protein can convert to the amyloid structure in so many diseases. Two hexa-peptide 
motifs within tau’s repeat domain (275VQIINK280 and 306VQIVYK311) have been shown to be 
crucial drivers of the amyloid formation of tau, despite the fact that they only represent ~3% 
of the total sequence (dependant on the isoform)68. Indeed, these sequences have the highest 
predicted b-sheet propensity and truncated forms of tau containing these motifs spontaneously 
aggregate69. Cryo-EM structures of the paired-helical filaments (PHFs) that compose NFTs 
also show that these structures are in the core of the fibrils, while the long N-terminus and 
shorter residual C-terminus of tau form a “fuzzy coat” surrounding this core (Figure 1.6b)70. 
What perturbations to tau could enable these motifs to drive amyloid formation? Another 
important characteristic of aggregated tau is that it contains many different post-translational 
modifications (PTMs). Most famously, tau in NFTs is found to be hyperphosphorylated. In the 
longest isoform, tau has a staggering 85 (80 Ser/Thr and 5 Tyr) potential phosphorylation sites. 
Unsurprisingly, phosphorylation is one of the primary mechanisms that regulates tau function 
in vivo. Normally, phosphorylation of tau is a key regulator for MT association, where the 
phosphorylation at key residues, in particular at various KXGS motifs, promotes the 
dissociation of tau71. When tau is bound to microtubules it does not fold into a consistent 
 15 
globular structure, however, the aforementioned hexa-peptide motifs have been demonstrated 
to be absolutely essential to stabilising the interface of tau with the junction of a/b tubulin 
heterodimers, forming a local hairpin motif72. From these observations it is clear when tau is 
performing its predominant function, these potentially pathogenic motifs are sequestered from 
inter-tau association. Thus, processes that encourage the dissociation of tau from MTs add to 
the pool of tau available for aggregation. This highlights a larger theme within protein science 
of a competition between physiological function and pathological association73.  
While hyperphosphorylation is only one aspect of tau dysregulation within AD, it is an 
important process to understand, and recent studies have begun to elucidate the driving forces 
behind this dysfunction. Several genetic studies support that Ab deposition is a prerequisite for 
AD-like tau hyperphosphorylation. Crosses of hAPP and hTau mice significantly increases tau 
deposition compared to the single transgene parents but has no effect on the levels of Ab 
deposits74. Likewise, when cultured rat neurons expressing hAPP are exposed to Ab oligomers 
isolated from AD patients, they exhibit neuritic dystrophy and tau hyperphosphorylation. 
However, if tau is knocked down before the exposure, no dystrophy is observed75.  More 
mechanistic studies have revealed that Ab oligomers can specifically activate mitogen-
activated protein kinase (MAPK) and glycogen synthase kinase-3b (GSK3b), both of which 
have tau as a well-established target76,77. Greatly supporting this is a study by Zheng and co-
workers using rat primary septal cultures showing that cultures exposed to Ab oligomers and 
specific inhibitors of either MAPK or GSK3b attenuated the level of tau phosphorylation 
compared to cultures solely exposed to Ab78. How Ab drives phosphorylation exactly is still 
poorly understood, but it is clear that tau hyperphosphorylation can cause dysfunction by more 
means than just freeing up tau to aggregate. Hyperphosphorylation has been shown to drive the 
mislocalisation of tau from the axon to the dendrites, promoting neuronal dysfunction 
independent of aggregation79. Different phosphorylation patterns also alter the degradation 
routes of tau by inhibiting protease cleavage or the ability to associate with the proteasome80,81. 
Improper tau phosphorylation has even been shown to disrupt the kinesin complex, thereby 
interfering with global axonal transport82. It is humbling to be reminded that all of this 
complexity in disease progression mentioned, and much more not discussed here, is solely 
attributed to one type of PTM on tau. Indeed, hyperphosphorylation for many years has 
eclipsed the significance of the other PTMs that tau undergoes, but there are many more83 
(Figure 1.6c). It is clear that more methods and tools for accurately studying phosphorylation 
as well as the myriad of less well understood PTMs including acetylation, methylation, 
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glycosylation, ubiquitinoylation, and more need be developed to elucidate the importance of 
these modification within normal physiology and disease. Once developed, these tools could 







Figure 1.6. Tau structure and modifications. (a) Regions of tau, the variable repeat within 
the microtubule binding domain is (R2) is coloured red. (b) Illustration of the Cryo-EM 
structure of tau fibrils where the core (purple/red) region is formed from the R3 and R4 repeats 
and the “fuzzy coat” is comprised of the rest of the sequence. (c) Location and identity of the 
known PTMs of tau. Figures (b) and (c) adapted with permission from references [70] and [83], 
respectively.  
 
1.1.5. Chemical kinetics for studying aggregation   
 
What are the mechanisms of amyloid growth? How fast are the proteins associating? 
What microscopic steps can be inhibited? These are all important questions that require a level 
of detail beyond bulk macroscopic observations, and theoretical frameworks for describing the 
microscopic mechanisms behind amyloid formation are therefore needed. This type of demand 
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draws many parallels from the classical field of chemical reaction kinetics and the use of rate 
laws to elucidate reaction mechanisms. In this field, the usual workflow begins with the 
proposition of a differential rate law for the reaction being studied:  
                                            𝑟 = 𝑘[𝐴]![𝐵]"…                                   (Eq. 1.1)                               
Where [A], [B], and so on are the concentrations of the different species involved in the 
reaction, the exponents a and b are the reaction orders, and k is the rate constant. In order to 
make this equation convenient for comparing predictions to experimentally measurable outputs 
an integrated rate law must be derived, this allows the variation of the reactant concentrations 
in time to be measured and compared to the model. To illustrate, in the simplest case of nA ® 
B the equations are as follows:  
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+ (𝑛 − 1)𝑘𝑡                                 (Eq. 1.3) 
This last equation (1.3) represents the integrated rate law, where [A]0 is the initial concentration. 







                                  (Eq. 1.4) 
A key observation from the above equation (1.4) is that the reaction half time should scale with 
the initial reaction concentration according to t1/2 µ [𝐴]!
g , where g = - (n – 1). This scaling 
component is directly related to the reaction order, or the number of microscopically interacting 
species. So, through this simple set of operations a now easily measurable macroscopic output, 
reaction halftime, can elucidate the microscopic mechanisms underlying the reaction. This 
powerful approach has been used innumerable times in physical organic chemistry, and a 
similar framework for the study of protein aggregation has evolved directly from these 
principles.  
 To begin to apply this methodology to protein aggregation, it helps to first think of the 
possible mechanisms that lead to an increase of fibril mass and number (Figure 1.7a). At a 
high level, there are two main classes of mechanisms: nucleation mechanisms that create new 
fibrils (primary nucleation, surface catalysed secondary nucleation, and fibril fragmentation) 
and growth mechanisms that alter the mass of existing fibrils (elongation and dissociation at 
the fibril ends). In the absence of any preformed fibrils, primary nucleation where monomers 
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associate to form competent nuclei is always the first event, it is therefore considered a primary 
pathway within the nucleation mechanisms. However, primary nucleation can occur through 
homogenous or heterogeneous mechanisms. In a heterogenous pathway, specific interfaces 
promote the formation of the growth competent nuclei, such as in the case of cholesterol for 
Ab84. While it may seem similar, heterogenous nucleation is distinct from the fibril surface 
catalysed secondary nucleation. This is because the fibril amount is varying throughout the 
course of the reaction, and thus the catalytic contribution is variable while it is fixed for 
heterogenous nucleation. Along with fibril fragmentation, surface catalysed nucleation falls 
into the secondary nucleation pathways that are dependent on fibril mass. These secondary 
mechanisms can also be thought of as autocatalytic feedback loops as they promote the 
exponential increase of aggregate number through their self-replication. For the growth 
mechanisms, monomer dissociation from the fibrils has been shown to be much slower than 
association and can be neglected85. With this picture of the different mechanisms underlying 
amyloid formation we can now attempt to place these into a differential rate law that describes 
the population balance of each of the relevant species that are present throughout the reaction, 
otherwise known as a master equation86. The derivation of the master equation for amyloid 
growth is beyond the scope of this thesis, but the importance of its application to global fitting 
of aggregation curves to elucidate mechanisms is hard to overstate. When coupled with 
procedures for reproducible aggregation reactions, which are monitored by the fluorescence of 
the dye thioflavin-T (ThT) that fluoresces upon intercalating in the b-sheets of amyloid fibrils, 
the exact microscopic mechanisms can be reliably determined. Properly fitting experimental 
aggregation reactions with this method has established the mechanisms for many disease 
associated proteins. A well-established example is how this method elucidated that the 
proliferation of Ab is heavily governed by surface catalysed secondary nucleation, shedding 
light on the mechanism behind decades of clinical observations of “halos” of oligomeric 
aggregates surrounding mature amyloid plaques in patient brains87. 
The utility of these equations extends further to studying the specific perturbations of 
inhibitors of aggregation as well, providing much needed guidance in drug development. This 
framework is again analogous to classical drug discovery for enzyme inhibitors, where the 
Michaelis-Menten equation is applied to fit experimental data in order to determine the 
mechanism of inhibition (i.e. competitive, non-competitive, etc.). Similar to this, the key 
approach to applying chemical kinetics to studying aggregation inhibitors is to realise that 
alterations to different microscopic events result in different macroscopic aggregation profiles 
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(Figure 1.7b)88. Alterations to the rates within the master equation can then be explored to find 
best match the experimental data, and thus determine the microscopic steps influenced by the 
inhibitor, which are a direct reflection of the potential species the inhibitor interacts with. This 
type of analysis is crucial for evaluating anti-aggregation-based therapeutics, as the haphazard 
inhibition of fibrillization can actually increase the production of toxic oligomers86. This type 
of approach has already facilitated the rational generation of several small molecule inhibitors 






Figure 1.7. Chemical kinetics of protein aggregation. (a) Illustration of the aggregation 
mechanisms that increase fibril number and/or mass. (b) Macroscopic perturbations of the 
aggregation profile brought about by various modes of inhibition. Figures adapted with 




1.2 Antibodies   
 
1.2.1. Antibody structure and diversity 
 
Antibodies have become a cornerstone in medicine for both therapeutic and diagnostic 
purposes and have become invaluable tools for basic research. Nearly all of the applications of 
antibodies derive from their incredible ability to bind to virtually any desired target with high 
affinity and specificity. The scope of applications of this fundamental capability is remarkable, 
from cancer therapy91, to the selective delivery of cytotoxic agents92, to enabling super 
resolution microscopy93, to medical imaging94, and even to act as catalysts95. These 
developments are reflected in the fact that the global market for monoclonal antibodies (mAbs) 
exceeded $100 billion USD in 2019. 
 The overall structure of antibodies is highly conserved between species. While there 
are several isotypes of antibodies in humans, the vast majority of antibody-based immunity is 
conducted by the canonical immunoglobulin G (IgG) type (which itself has four subclasses). 
IgG’s are large (~150 kDa) and are composed of four peptide chains linked together by 
disulphide bonds, two larger heavy-chains and two smaller light-chains forming an overall “Y” 
shape (Figure 1.8a)96. The stem of the “Y” is formed by the C-terminal regions of the heavy-
chains and is termed the fraction-crystallizable (Fc) and is responsible for signalling with other 
entities in the immune system through highly conserved N-glycosylation sites. Each arm of the 
“Y” is identical and is termed the antigen-binding fragment (Fab), meaning a full IgG contains 
two antigen binding sites. The Fab region can itself be differentiated into one constant and one 
variable domain, each consisting of segments from the light and heavy-chains. The variable 
regions (Fv) of the heavy and light chains (VH and VL, respectively) contain the antigen binding 
sites. Binding is specifically mediated through the 3-complementary determining region (CDR) 
loops on each variable fragment (Figure 1.8b). The sequence and size of these loops varies 
wildly between antibodies, understandably since these are the regions responsible for 







a         b 
 
Figure 1.8. Antibody structure. (a) Structure of a full-length IgG, heavy chains are shown in 
blue and light chains in green with the CDRs of each in red (PDB: 1IGT). (b) Close up of the 
CDR loops of the variable domain of the heavy chain with each of the three loops indicated.  
 
 There are a few notable exceptions to the general IgG structure. The sera of the 
Camelidae family contain very unusual heavy-chain antibodies (HCAbs) that are completely 
devoid of light-chains and lack the first constant domain97 (Figure 1.9a). Quite remarkably, 
similar immunoglobulins have also been found in certain species of shark98. There are several 
subtypes of HCAbs found in camelids with different hinge region lengths. The minimal binding 
entity that conventional heterotetrameric IgGs can be reduced to is the tethered VL and VH 
fragments (scFv). However, since HCAbs lack a light chain, they can be reduced to a single 
variable heavy-chain fragment (VHH), termed a nanobody (Nb) (~14 kDa depending on the 
sequence) (Figure 1.9a). VHHs differ from the VH of normal IgGs in a few significant ways 
that enable them to function in the absence of a light-chain. Conventional VH’s have several 
highly conserved hydrophobic amino acids at the interface with the VL, in camelid VHHs these 
are mutated to smaller or hydrophilic amino acids to create a less “sticky” surface that can be 
stable in the absence of a binding partner99. These structural adaptations have now been 
incorporated into human VHH’s in order to create stable fully human single domain antibodies 
(sdAbs). Another consequence of removing the light chains is that antigens can only be 
recognized by 3 CDRs instead of 6. VHHs overcome this loss of interacting surface by 
extending the CDR loops, the CDR3 loop most significantly100 (Figure 1.9B). Their reduced 
size and extended loops have famously enabled sdAbs to access “cryptic” epitopes buried in 
proteins previously inaccessible with conventional antibodies101. Reducing an antibody down 
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to its minimal binding element also allows for specific binding to the desired target but without 
eliciting the immune response, which again is mediated through the Fc region. This is highly 
desirable when inflammation should to be avoided, such as with neurological diseases. 
Additionally, the reduced size of sdAbs makes them more efficient at tissue penetration and 
even aids them in crossing the blood-brain barrier102.  
 However, there are certain physiological drawbacks with the reduced size and 
complexity of sdAbs. The drawbacks are not only limited to the avidity, as their small size is 
also significantly lower than the renal threshold of 60 kDa causing their serum half-life to be 
significantly shortened. Their lack of an Fc region means they cannot engage the neonatal Fc 
receptor (FcRn) as well, which normally protects IgGs from lysosomal degradation103. Thus, 
this further reduces their serum half-life.  
a                                                        b  
 
Figure 1.9 Camelid antibodies and nanobody structure. (a) Schematic representation of the 
different types of antibodies found in camelid serum and their minimal binding domains. (b) 
Structure of a canonical camelid nanobody with the extended CDR3 loop in red, CDR2 in green 
and CDR1 in blue. Key amino acid positions that would interact with a variable light-chain are 
shown in their 3-letter code, these have been mutated from less favourable amino acids to 
increase stability when exposed to the solvent or are covered by the extended CDR3 loop. 
Figures adapted with permission from reference [97].  
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1.2.2. Antibody maturation in vivo and endogenous functions 
 
 Within normal physiology, antibodies are generated through a series of processes in the 
immune system with the ultimate purpose of binding foreign antigens to mediate the host 
defence response in adaptive immunity towards pathogens. New antibodies are generated 
through a short lived but rapid evolutionary process that is confined within an individual’s 
immune system104 (Figure 1.10). The development begins with the capture and presentation 
of a foreign antigen by follicular dendric cells (FDCs) inside compartments called germinal 
centres. In these centres, B-cells present highly diverse antibody paratopes that have been 
generated through V(D)J recombination and somatic-hypermutation (SHM), which creates a 
large amount of diversity in the CDR loops by a localised error-prone DNA replication process. 
These paratope presenting B-cells are then subjected to a competition for binding the antigen 
presenting FDCs, where unbound B-cells with poorly performing paratopes are removed 
through apoptosis, thus refining the library. The bound B-cells are then proliferated and 
undergo further rounds of SHM and selection, successively increasing their binding affinity 
and specificity. Ultimately, when the binding affinity is optimal, the B-cells are transformed 
into memory B-cells that now can rapidly generate their refined antibody in response to re-
exposure of the foreign particle105. 
 
Figure 1.10. In vivo antibody maturation. Illustration of the process and components 
responsible for the somatic hypermutation leading to mature antibodies for adaptive immunity. 




 Target engagement by an antibody can lead to several outcomes. As mentioned 
previously, the Fc region of the antibody is responsible for signalling to immune cells within 
the body through Fc receptors. When an antibody is bound to a target, it can be marked for 
clearance through phagocytosis by bringing together the target and phagocytes through this 
dual interaction in a process called antibody opsonisation106 (Figure 1.11a). This type of 
activity is regulated by the patterns of glycosylation on the Fc region of the antibody. 
Antibodies are also capable of mounting a defence solely through their own action, such as by 
blocking the activity of a critical region of the pathogen crucial for biological activity, such as 
cellular entry receptors of a virus107 (Figure 1.11b). The multi-avidity of antibodies enables 
yet another mechanism of protection through a network of interactions between several 
antibodies and their targets in a process called agglutination108. This mechanism limits the 
spread of the pathogen or even precipitates them out of solution and localises them for efficient 
clearance by other immune cells (Figure 1.11c).  
 
Figure 1.11. Modes of antibody function. (a) Opsonisation of a pathogen (blue) occurs when 
an antibody (green) marks the object for clearance through binding its antigen. (b) A pathogen 
can also be neutralised through antibodies completely coating the part of entity crucial for 
pathogenicity. (c) The multi-avidity of antibodies can also lead to the agglutination of many 
pathogens that can cause them to precipitate from solution and thus loose pathogenicity. (d) 
Antibody mediated phagocytosis is triggered when Fc receptors (red) bind to an engaged 




1.2.3. Classical directed antibody maturation   
 
 For the last several decades, antibody maturation in biopharma has been driven by 
attempting to mimic the rapid evolutionary process utilised by nature. A number of techniques 
to accomplish this have been developed and are collectively called directed evolution. While 
directed evolution is being applied in ever increasingly sophisticated ways for complex 
functions, for antibody binding the techniques are relatively straightforward and usually fall 
into the category of display methods109. Regardless of the approach, all directed evolution 
projects begin with the diversification of the starting protein of interest’s DNA. The starting 
protein is usually a naturally occurring protein with some of the already desired characteristics 
or activity109. The diversification can be achieved through multiple approaches such as error-
prone PCR or saturation site-directed mutagenesis. The power of directed evolution techniques 
then comes through the linkage of the coding sequence to the physical activity of its product. 
For display methods this can be achieved through multiple approaches including phage display, 
ribosome display, yeast display, and mRNA display (Figure 1.12a-c). While the vehicle for 
the protein and its encoding DNA/RNA is different in each of these, the principles are largely 
the same. The diversified library is exposed to the immobilised desired target and undergoes 
competitive binding, then poorly bound or unbound candidates are washed away from the 
displayed antigen. After several rounds of selection high-affinity, antibodies are isolated and 
sequenced. The selection of the platform depends on the size of the protein to be developed; 
yeast-surface display is capable of evolving full IgGs thanks to the eukaryotic quality control 
machineries yeast contain to assist with protein folding. However, this comes at a cost of the 
size of the library that can be screened (~107 variants), largely limited by the transformation 
efficiencies of the yeast themselves110. Following this trend, ribosome and mRNA display can 
have libraries as large as 1013 variants since they are entirely in vitro and therefore not limited 
by transformation, but due to the lack of quality control mechanisms these are best suited for 










             a                              b                          c 
 
Figure 1.12. Examples of in vitro display methods. (a) Phage display relies on E. coli to 
synthesise and fold proteins that are fused to the coat proteins of viruses. (b) Ribosome display 
takes advantage of conditions to prevent release of the protein and mRNA (c) mRNA display 
utilises puromycin to covalently link a protein with its mRNA after translation and release from 
the ribosome.  
 
1.2.4. In silico antibody development 
 
 The combination of in vivo and in vitro approaches to antibody development have 
enabled the great success of antibody-based therapies that we have seen in the last 25 years. 
However, these approaches still face limitations in a number of areas within the development 
process112. Several target classes remain as difficult targets for discovery programs, including 
membrane proteins, aggregation-prone targets, selection of agonists versus antagonists of 
biological pathways, and highly homologous targets. While both the classical immunization 
and in vitro approaches for antibody development offer a vast repertoire of unique sequences, 
these techniques primarily select for simply the tightest binders of the target, which usually 
occurs at immunodominant epitopes that may not be the functionally relevant sites112.  If there 
are lower affinity binders at the desired sites, these are not likely to be selected through these 
methods. This critical fault has driven the development of advanced experimental apparatuses 
to enable selection based on functional screening rather than binding. Nonetheless, these 
approaches are costly and may not be applicable in every case113. Ultimately, this has led to 
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the development of a number of in silico approaches to design antibody paratopes to target 
weakly immunogenic sequences or specific functional sub-domains. The successful 
development of approaches in this area of research could make massive strides in streamlining 
and reducing the cost of antibody drug discovery.  
 Intrinsically disordered proteins (IDPs), a major class of proteins involved in a wide 
range of biochemical processes, and the class that many amyloidogenic proteins belong to, can 
pose as difficult targets for classic antibody development techniques114. This is partly due to 
their largely linear nature which makes it difficult to isolate antibodies for specific functional 
or pathological sub-domains. To address this, a computational method has recently been 
developed to generate paratope sequences against linear targets115. The method is centred on a 
cascade approach for the generation of complementary sequences derived from the analysis of 
structures in the Protein Data Bank (PDB). Once a query target sequence is chosen, the PDB 
is scoured for structures where pieces of that sequence, of three or more residues, is engaged 
in a face-to-face b-strand, either parallel or antiparallel. Hopefully, the search identifies a series 
of fragments (b-pairs) that overlap to cover the entire queried sequence, this library of 
complementary sequences can then be assessed for their compatibility for merging into a 
peptide that can cover the entirety of the target. In brief, to accomplish this first the b-pairs 
must be of the same type of (i.e. both antiparallel), they must contain at least two overlapping 
residues at the merging junction, and the hydrogen bonding pattern of the backbone of 
overlapping region must match. In the end, the principle of this method is that, once these 
complementary sequences are merged, the ability of each fragment to interact with the target 
in a b-sheet is additive and will contribute towards a larger overall b-sheet interaction with the 
entire linear target (Figure 1.13a). This sequence can then be grafted into the CDR loops of an 
antibody to confer binding, and has been successfully applied to develop single-domain 
antibodies against a-synuclein as well as a panel against the sequence of Ab and has produced 
significant data to support the binding site is indeed for the desired location through 
experiments like the loss of binding after proline insertion into the epitope (Figure 1.13b,c).  
 When targeting aggregation prone regions of proteins, there is a high risk of producing 
poorly soluble paratope sequences within the antibody116,117. To avoid this, solubility 
prediction algorithms can be run in parallel to evaluate engineered sequences116. From an 
industrial perspective, this is vital as many candidate antibodies that display desired activity 
may still be unfeasible for production if their solubility limits formulation strategies or if their 
instability is too great119. An example of a solubility prediction algorithm is CamSol, and its 
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application in tandem with rational paratope design represents what is emerging as the third 
generation of discovery methods for antibodies (Figure 1.14d). 
 
Figure 1.13. Rational design of antibodies. (a) Schematic of the creation of a complementary 
peptide graft for the NAC region of a-synuclein. Three different properly overlapping 
sequences found in the PDB engaging the desired sequence in a b-strand conformation are 
combined to create the desired interaction. (b) A Fluorescence competition assay of the 
designed single domain antibody for labelled a-synuclein, blue is in the absence of non-
labelled competitor, red is in the presence of equimolar unlabelled a-synuclein and purple is 
in the presence of equimolar unlabelled a-synuclein with a proline inserted in the target 
sequence (P73). (c) Panel of single-domain antibodies designed to span the length of Ab. (d) 
Illustration of various rational design strategies to improve antibody function, stability, and 
solubility. Figures adapted with permission from references [115] and [112] respectively.   
 
 
1.2.5. Antibody use in Alzheimer’s disease  
 
Antibodies and fragments thereof have been developed or discovered against a wide 
range of protein states beyond the native state, including transition and aggregated states112. In 
the case of Ab, Glabe and co-workers have leveraged classical immunization techniques by 
injecting rabbits with stabilised Ab40 oligomers covalently linked to gold nanoparticles to 
obtain a panel of oligomer specific mAbs120. The variable reactivity of this panel revealed that 
amyloid oligomers are structurally diverse and at least a subset can propagate their structures 
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in a prion like fashion. Prior to this study, Cattaneo and co-workers had developed a panel of 
intracellularly stable oligomer specific scFvs through a more complex intracellular selection 
platform121. The platform is based on screening scFv cDNA libraries in yeast derived from 
naïve and Ab-immunised mice for their ability to associate with an Ab-bait that initiates the 
translation of an essential gene. This study yielded unique scFvs that displayed both linear 
sequence specificity and conformational sensitivity likely arising from the more 
physiologically relevant conformations and the possible oligomers that the Ab-bait adopts in 
the intracellular environment compared to other campaigns that utilise immobilised Ab122.  
The power of antibodies to treat infectious diseases and cancer similarly led to the 
investigation of their ameliorative ability in AD beginning in the late 1990’s. Active and 
passive immunization strategies have both been explored clinically, although passive 
immunizations have become the much more dominant approach after an unfortunate early trial 
of an active immunization observed the development of T cell mediated meningoencephalitis 
in a significant number of patients123. For passive strategies, the dominant target for the last 
two decades has been Ab, based on the amyloid hypothesis of AD (although several novel 
therapies based on other targets in the disease cascade have begun being explored more 
recently)124. A plethora of antibodies, all full-length IgG mAbs, against various forms of Ab 
have been developed by a handful of pharmaceutical companies (Table 1.2), the first being 
bapineuzumab from Pfizer125. Famously, all but one of these candidates has failed to show 
significant efficacy in phase II or III of clinical trials, where the primary measures of efficacy 
are cognitive improvements and the reduction of fibrillar Ab in the brain as measured by 
positron emission tomography (PET) scans. The common causes cited for the failure of these 
trails have been either administrating too late in the pathology of the disease, therefore the 
activity of these agents is too little too late, or that the dosing was insufficient126. From a 
practical perspective, the latter issue is one that might potentially be more tractable. This is 
because most of the mAbs against Ab have exhibited well tolerated safety at the doses that 
have been explored127. The former issue is of a somewhat more convoluted nature since two 
perspectives can be taken: either early intervention is critical for any treatment benefit, or in 
late disease stages with advanced Ab deposition modest clearance is simply insufficient or 
even irrelevant58. Despite the unresolved ambivalence, current trials are unquestionably aiming 




Antibody Manufacturer Origin Subclass Epitope 
Bapineuzumab Pfizer/Janssen Humanized IgG1 AA 1-5 
Solanezumab Eli Lilly Humanized IgG1 AA 16-26 
Gantenerumab Hoffman-La Roche Human IgG1 AA 3-12, AA 18-27 
Crenezumab Genentech Inc. Humanized IgG4  AA 13-24 
Ponezumab Pfizer Humanized IgG2 AA 30-40 
BAN2401 BioArctic, AB/Esai 
Co.  
Humanized IgG1 Protofibrils 
Aducanumab Biogen Inc. Human IgG1 AA 3-6 (conformation 
specific) 
Table 1.2- Clinical monoclonal antibodies for Ab 
 
The antibody that is the closest to Food and Drug Administration (FDA) approval for 
AD treatment is aducanumab by Biogen, which is currently in an extended phase III trial. 
However, the trial was only extended after significant post hoc analysis after it was initially 
discontinued by an earlier assessment claiming it was unlikely to meet its target endpoint128. 
As seen in Table 1.2, aducanumab targets the N-terminus of Ab (residues 3-6), but only when 
it is in a conformational epitope found in oligomers and fibrils129. To attempt to rationalise why 
aducanumab achieved relative success compared to its predecessors, a kinetic study of the 
aggregation inhibition of a panel of clinical Ab antibodies was recently conducted130. This 
illustrated that aducanumab’s binding mechanism is the most efficient at reducing the 
oligomeric population during the reaction progression, perhaps explaining why aducanumab 
also showed the highest reduction of amyloid plaques in the clinic as measured by PET (Figure 
1.14a,b). These findings indicate that previous attempts to generate clinical Ab antibodies were 
likely generated by a process that does not fully appreciate the complexity of the aggregation 
reaction. If aducanumab does achieve FDA approval, it is by no means the end of the race for 
a disease modifying AD therapy; as mentioned above, a post hoc analysis was needed to justify 
the continuation of aducanumab’s trial. This analysis revealed that only patients in the early 
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stage of the disease receiving the highest dose exhibited any clinical benefit128. This means that 
patients in the midst of the disease likely still need alternative therapeutic approaches.  
 a      b 
 
Figure 1.14. Aducanumab in vivo and in vitro activity. (a) Axial slices of PET images 
showing amyloid burden in the posterior of patient brains on various dosages of Aducanumab 
after 1 year of treatment. (b) Graph displaying the correlation of the measured changes in 
oligomer flux of the aggregation reaction in the presence of various clinical antibodies with 
their reported cognitive improvement. Figures adapted with permission from references [129] 
and [130] respectively.  
 
1.3 Bioorthogonal chemistry  
 
1.3.1. Chemistry in living systems and bioorthogonal chemistry  
 
Life has evolved to perform chemical transformations under a relatively narrow range 
of conditions. Biological systems operate exclusively between 0 and 100 °C, in aqueous 
solution, with limited functional groups and metal ions, and in highly dense and heterogeneous 
environments. To perform the chemical transformations life requires under these conditions, 
nature has evolved enzymes as incredible biological catalysts and has created specialised 
organelles with optimised conditions for particular reactions, amongst many more adaptations. 
Since the dawn of biochemistry, scientists have tried to develop approaches to subtly 
manipulate and probe biological processes within these confined conditions. Great advances in 
this realm were enabled through the advent of fluorescent proteins and efficient genetic 
engineering tools, which enabled proteins of interest to be selectively labelled at their synthesis 
for monitoring131. However, there are a number of limitations with genetic labelling strategies. 
These approaches lack temporal control, cannot label other biomolecules such as lipids or 
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nucleic acids, cannot study post-translational modifications, and the large protein tags can also 
interfere with the endogenous function of the protein of interest132. These limitations, amongst 
others, have prompted chemists to work alongside biologists to develop reactions that can 
selectively target unique functional groups while not interfering with other biological 
processes, otherwise known as bioorthogonal chemistry.  
 For a reaction to be considered useful from a bioorthogonal perspective, it needs to 
meet some specific criteria: 1) it needs to be compatible with aqueous media, 2) at 
physiological pH, 3) have fast reaction rates at physiological temperatures and low reactant 
concentrations, and 4) it needs to be inert to the functional groups in all the various biologically 
active molecules133. From the perspective of in vivo protein modification, none of the canonical 
amino acids can function as a unique moiety for tagging. To overcome this, early examples of 
bioorthogonal reactions relied on uniquely reactive peptide motifs composed of natural 
sidechains but in an uncommon sequence.  An early example of this is the tetracysteine motif 
used for selectively labelling proteins with membrane permeable fluorescent biarsenical 
compounds like FlAsH and ReAsH134 (Figure 1.15a). Other approaches similar to this rely on 
peptide sequences capable of coordinating functionalised metal ions like histidine rich 
sequences and Ni-NTA probes as well as the more nuanced use of trans-splicing inteins135,136. 
However, with using natural functional groups there is a very limited diversity of approaches 
for in vivo chemical labelling.  
While less complex than labelling inside the cellular environment, several aspects of 
selective protein modification in vitro with purified proteins still remain challenging. The 
purpose of in vitro labelling can go far beyond imaging aides, such as the attachment of 
cytotoxic reagents in the case of antibody-drug conjugates137, adding poly-ethylene glycol 
(PEG) chains to improve the serum half-life of a protein,138 or studying difficult to access PTMs 
and much more139. The nature of these applications places great weight on the homogeneity of 
the conjugation reaction, the stability of the conjugate, and the versatility of the chemistry. In 
vitro labelling has typically relied on the unique reactivities of specific canonical amino acids, 
most famously the nucleophilicity of lysine and cysteine residues (Figure 1.15b). However, 
traditional conjugation approaches at these and other residues have long had difficulties with 
meeting some of the above criteria, such as the challenges with NHS esters and malimides140. 
This has led to the exploration of more advanced conjugation reagents, as well as the 
investigation of the introduction of more appropriate amino-acid functional groups into 
proteins. The latter approach is attractive for a number of reasons, as inserting a new non-
canonical amino acid can enable huge advancements for both in vivo and in vitro conjugation 
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issues, and the research in this area has been experiencing rapid development over the last two 
decades.  
 
          a 
 
 
        b 
 
Figure 1.15. Labelling of endogenous amino acids. (a) Reaction of the fluorescent biarsenical 
compound ReAsH with a tetracysteine tag on a protein. (b) Traditional conjugation strategies 
at cysteine (yellow) and lysine (blue) (1 = thiol exchange, 2 = alkylation of a-halocarbonyl 
electrophiles, 3 = maleimide Michael addition, 4 = NHS-ester amidation, 5 = 
isothiocyanate/isocyanate addition, 6 = reductive amination).  
 
1.3.2. In vivo incorporation of non-canonical amino acids 
 
 The major limiting factor for the chemical space available for proteins is that the 
cellular machinery for synthesis is, for the most part, confined to the 20 canonical amino acids. 
One way that nature has introduced greater functional diversity for proteins is through the 
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PTMs is enabled through the evolution of highly specific enzymes capable of distinguishing 
the appropriate residues in a specific motif, a luxury that chemical biologists do not have for 
novel modifications. However, artificially expanding the lexicon of amino acids to include 
ones with novel functional groups can remedy this situation, and numerous approaches to 







Figure 1.16. Residue specific unnatural amino acid incorporation. (a) Illustration of using 
an analogue of methionine to and a media shift to incorporate the unnatural amino acid at 
residue specific sites throughout the protein. (b) Examples of phenylalanine analogues 
incorporated through the mutation of the endogenous E. coli aaRS.  
 
 The simplest method for incorporating non-canonical amino acids is through residue-
specific incorporation141. This approach utilises a chemically similar analogue to a natural 









synthetase (aaRS), leading to a partial replacement of the natural amino acid throughout all 
proteins in the organism (Figure 1.16a). An early example of the utility of this approach was 
back in the 1950s when it was discovered that selenomethionine could be incorporated into 
bacterial proteins in place of methionine. This facilitated the phasing of many protein crystals 
thanks to the anomalous scattering that the heavier selenium atom enabled142. To achieve closer 
to quantitative replacement with an unnatural amino acid, auxotrophic strains of bacteria (ones 
deficient in the biosynthetic machinery necessary to make an amino acid) must be used. 
Keeping the transgenic protein under a strong repressor, the bacteria can then be grown in rich 
media with all 20 amino acids initially, and then shifted during expression into media 
supplemented with the designed analogue replacing the essential amino acid. Without any 
genetic manipulation, the range of unnatural amino acids that can be introduced in a residue 
specific manner is limited, as the analogues must be significantly similar to the natural amino 
acid or else their activation by the endogenous aaRS is too slow or even undetectable. To 
overcome this, to a certain extent, several different aaRS’s have been mutated to be more 
accommodating to unnatural analogues by modifying either the editing domain (responsible 
for hydrolysis) or their amino acid binding pocket143. In the case of the E. coli. phenylalanine 
aaRS, these types of mutations have enabled the residue-specific incorporation of a variety of 
uniquely reactive analogues144 (Figure 1.16b). Residue-specific incorporation of reactive tags 
has enabled studies on the global synthesis, localisation, and degradation of proteins145,146. 
Such indiscriminate incorporation has clear limitations however, and in order to incorporate 
















Figure 1.17. Site-specific designer amino acid incorporation. (a) Illustration of the 
mechanism of amber codon suppression for the expansion of the genetic code. (b) Schematic 
representation of the positive and negative selection directed evolution steps to engineer an 
orthogonal aaRS/tRNA pair. The positive step selects for the ability to incorporate an amino 
acid into an essential protein for life while the negative step reduces promiscuity by removing 
the designer amino acid from the media and incorporating the amber codon in a toxic protein 
product.  
 
 To site-specifically integrate unnatural designer amino acids, genetic code expansion 
technology must be used. In this approach, an orthogonal aaRS and tRNA pair are engineered 
to insert the designed amino acid in response to the amber stop codon in mRNA (UAG) (Figure 
1.17a)146. This approach was pioneered by Peter Schultz and co-workers and has greatly 
expanded the repertoire of unnatural amino acids. Originally, the approach was made possible 
by engineering the tyrosine aaRS/tRNA pair from the archaebacterium M. jannaschii to 
recognize the amber codon, integrate unnatural tyrosine analogues, and function orthogonally 
to the E. coli protein synthesis machinery147. Systems of this type have now been engineered 
from multiple organisms to function in prokaryotes all the way to whole multicellular 
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organisms and have allowed for the incorporation of over 100 disparate unnatural amino 
acids141. The process for developing these systems now has a relatively standard workflow 
consisting of two directed evolution steps. First, the aaRS/tRNA pair undergo a positive 
selection step where the unnatural amino acid must be incorporated for the function of a life-
giving protein, selecting for any pairs that allow for an amino acid incorporation, and then a 
negative selection step to reduce the promiscuity of the pair for amino acids other than the 
desired designer unnatural one (Figure 1.17b). The diversity of functional groups that genetic 
codon expansion technology introduces has enabled a myriad of in vivo protein conjugation 
strategies that have facilitated some significant breakthroughs. A reaction that has proved 
particularly useful in this context is the [4+2] cycloaddition of 1,2,4,5-tetrazines and various 
dienophiles, also referred to as the inverse electron demand Diels-Alder reaction (IEDDA) 
(Figure 1.18a,b)148. This is due to its biocompatibility, catalyst free reactivity and, in 
particular, its large second order rate constant. Either the dienophile or the tetrazine can be 
incorporated into the protein. A realm that this reaction holds particular promise for is 
therapeutics thanks to the aforementioned qualities, such as for pro-drug activation of antibody-
pro-drug conjugates (Figure 1.18c)149. Compared to conventional ADCs, this approach is 
markedly safer since the non-specific degradation of the linker simply results in a loss of 
reactivity rather than the release of the cytotoxic cargo. While genetic code expansion 
undoubtably has an important role to play for the future of biological research, there is a long 
road ahead to see the full maturity of this technology. However, great strides are being made 
to solve issues surrounding the technique, such as the loss of fitness in cells. This is due to 
read-through of endogenous proteins using the amber stop codon and the challenge of 
incorporating more than one unnatural amino acid at specific sites. Potential solutions to these 
issues include the synthesis of a recoded E. coli genome with reduced codon usage (61 instead 
of 64) allowing for the usage of the deleted codons for new amino acids and the creation of a 




Figure 1.18. IEEDA reaction for in vivo bioorthogonal labelling. (a) Frontier molecular 
orbital diagram of the IEEDA reaction (EDG = electron-donating group, EWG = electron-
withdrawing group) and an example of in vivo labelling rate of GFP bearing a tetrazine UAA 
with trans-cyclooctene. (b) Schematic of pro-drug release by an APDC through an IEEDA 
decoupling reaction. Figures adapted with permission from reference [148].  
 
1.3.3. Post-expression mutagenesis  
 
 Site-directed genetic mutagenesis revolutionised molecular biology, especially in the 
way scientists investigate and modulate protein function. The abovementioned genetic code 
expansion technology is now further expanding the power of gene-based mutagenesis. 
However, before these technologies existed, the first ever site-selective point mutation was not 
achieved through genetic manipulation, but by chemical means on a purified protein. In 1966 
both the research groups of Koshland and Bender independently converted the active site serine 
residue of substilin to cysteine using a two-step chemical synthesis (Figure 1.19a)152,153. After 
the 1970s, the rise of recombinant protein technology led many to believe that mutagenesis via 
chemical means was obsolete. Barring a few notable examples in the context of improving 
native chemical ligation (NCL) to overcome its reliance on cysteine154,155, progress in the field 
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saw a very long hiatus until the mid 2000s. Chemical biologists were driven to reinvestigate 
chemical mutagenesis by the potential utility of a general approach for post-expression amino 
acid interconversion. This approach would utilise a precursor residue capable of being 
transformed into a wide variety of natural and unnatural sidechains, potentially offering a wide 
array of chemical diversity from a single purification of the precursor bearing protein. Thus, 
both enhancing the efficiency of production and expanding the array of functional groups 
available for the protein compared to traditional mutagenesis.  
 From the description, it is clear that the most important initial step in developing a 
general chemical mutagenesis method is the selection of a synthetically versatile amino acid. 
For an amino acid to be considered synthetically versatile it must, by default, have reactivity 
of a bioorthogonal nature in order to not interfere with other regions of the protein. Genetic 
code expansion has indeed been used in this context to provide amino acids with this quality. 
Shultz and co-workers incorporated p-borophenylalanine in proteins to act as a traceless 
affinity tag, as the boronic acid moiety binds to polyhydroxylated resins and can then be 
converted to either tyrosine or phenylalanine via bioorthogonal means after purification 
(Figure 1.19b)156. The access to just two amino acids from a reactive precursor is far from a 
general approach but highlights a creative application of this technology. To gain true 
generality, a smaller and more versatile amino acid must be used. As far as general reactivity 
trends go, none of the canonical amino acids are strong electrophiles. Therefore, the placement 
of a minimal electrophilic amino acid could be an ideal candidate for a synthetically versatile 




Figure 1.19. Early examples of chemical mutagenesis. (a) Strategy for the first ever site-
specific amino acid conversion on substilin, the active site serine was first converted to a strong 
leaving group that could then be displaced by the thioacetate, which upon hydrolysis yields the 
free thiol of cysteine. (b) P-borophenylalanine as a slightly more diverse chemical precursor to 
the amino acids phenylalanine and tyrosine.   
 
1.3.4. Dehydroalanine: Installation and modification    
 
 The electrophilic nature of Dha has been utilised in several organisms, particularly for 
the synthesis of complex peptide macrocycles. For example, the bacteria Lactococcus lactis 
uses Dha as an intermediate in the synthesis of the commercially used antibacterial peptide 
nisin (Figure 1.20a)157. In nisin’s biosynthesis, serine is enzymatically converted to Dha 
through a phosphorylated intermediate, which is subsequently used as a Michael-acceptor for 
the creation of a thioether linkage to cyclise the peptide at multiple sites. The a/b unsaturated 
system of Dha is the unique chemical structure among the canonical amino acids that confers 
the electrophilicity of the residue and facilitates conjugation through Michael additions and 
other reactions. While biosynthetic machinery is capable of selectively converting serine 
residues to Dha, from the perspective of a chemist, this is not a particularly attractive route of 
installation. Namely, this is because serine is one of the most common amino acids, so 
selectivity will undoubtably be an issue and the elimination of the hydroxyl group typically 
requires pH conditions that would be incompatible with many proteins. Again, genetic code 
 41 
expansion technology has been used to provide an alternative route through the incorporation 
of phenylselenocysteine, which can be converted to Dha through oxidative elimination158. 
However, an even more easily accessible and appropriate precursor to Dha is cysteine. This is 
because cysteine is one of the least common amino acids and its site-selective installation does 
not require an engineered organism. From cysteine, there are four clear possible routes for 
conversion to Dha: reductive-elimination of cysteine disulphides, base-mediated elimination 
of disulphides, oxidative elimination of cysteine, and bis-alkylation-elimination of cysteine 
(Figure 1.20b)159. Of these strategies, the bis-alkylation-elimination approach has proven to 
be the preferred route, as it can be accomplished with easily accessible reagents, under mild 






Figure 1.20. Dha in nature and its chemical installation. (a) Synthesis of ring A of Nisin 
through the Michael addition of a cysteine residue to an enzymatically installed Dha residue. 
(b) Chemical strategies for the installation of Dha from solvent accessible cysteine residues on 
peptides and proteins.  
 
 Once installed on a protein, the power of Dha for chemical mutagenesis becomes 
readily apparent from the diverse routes of modification it enables. As mentioned above, the 






































































































canonical amino acids. Using this approach, proteins bearing Dha have been modified through 
both thia and aza-Michael additions with a plethora of sidechains159-162. Due to the minimal 
linking group resulting from the addition (a carbon and a single heteroatom), many complex 
PTM mimetics have been able to be installed on proteins using Dha to enable the accurate 
study of their function, despite the fact that modifications at Dha likely result in an epimeric 
mixture of the installed sidechain (Figure 1.21a). For example, Davis and co-workers used 
Dha mediated synthetic phosphorylation of the disease relevant kinase p38a to accurately 
study therapeutic inhibitors163. The activity of p38a is regulated by phosphorylation at Thr180, 
and it is difficult to activate p38a non-enzymatically as typical phospho-mimetic mutations 
like Asp/Glu do not activate p38a to its endogenous substrate ATF2164. By creating a cysteine 
mutant at Thr180 and then converting to Dha, the researchers were then able to create a 
phosphocysteine (pCys) residue through a Michael addition with sodium thiophosphate, a very 
close analogue to pSer. The resulting p38a(Thr180pCys) mutant was capable of 
phosphorylating ATF2 in vitro to levels in line with studies using biologically derived mixed 
samples (> 10% non-phosphorylated and ~30% diphosphorylated) (Figure 1.21b)163. Closer 
analysis of the time course by LC-MS revealed that the synthetically mono-phosphorylated 
form also favoured mono-phosphorylation of ATF2, while the mixed samples containing di-
phosphorylated p38a favoured di-phosphorylation of ATF2, thereby shedding light on a 
previously unknown mechanism. Creation of the pure active form through synthetic means 
also enabled the unequivocal assignment of modes of inhibition (i.e. Type I/II) to a panel of 
inhibitors and quantify their cooperativity. Michael-additions at Dha also hold great promise 
in the realm of biotechnology. Bernardes and co-workers successfully used Dha to create an 
ADC with Thiomab (anti-Her2 antibody) and Crizotinib (FDA approved kinase inhibitor) by 
ligating the drug directly to the antibody through an aza-Michael addition of the piperidine 
moiety within the drug itself161. This created product with a homogenous drug-to-antibody ratio 
of 2 and a plasma stable tertiary amine as the linker and furthermore improved the cell-killing 












Figure 1.21. Michael additions at Dha and mimicking a disease relevant PTM. (a) 
Epimerization upon the nucleophilic attack of Dha by the proton transfer from water to the 
enolate intermediate from above and below. (b) 1- Electrophoretic radioassay of ATF2 
phosphorylation by various forms of P38a, showing that the synthetic phosphorylation 
(P38apC) is a valid mimic. 2- Coomassie stain verifying the total ATF2 levels. 3- LC-MS 
quantification of the degree of ATF2 phosphorylation, illustrating that the mono-
phosphorylated P38a favours mono-phosphorylation of its target. Figure (b) adapted with 
permission from reference [163].  
 
 While the literature supports that Michael additions at Dha with thiols and amines has 
its clear utility in studying PTMs, chemists have developed more advanced reactions to install 
even more accurate mimics. It is clear that this necessitates a reaction that can create carbon-
carbon sp3 bonds at the b carbon of Dha. To accomplish this, Davis and co-workers have 
developed a radical mediated ligation of halogen bearing precursors to Dha (Figure 1.22)165. 
This approach has enabled the installation of a wide variety of exact PTMs found in nature 
(except for their epimeric mixture). While this reaction represents an exciting step forward 





















anaerobic conditions means considerably more optimisation is needed for each reaction 
compared to the aforementioned Michael additions.  
 
Figure 1.22. C(sp3)-C(sp3) bond formation at Dha. Schematic of the possible reaction routes 
for a free radical mediated C(sp3)-C(sp3) bond formation at Dha with halogen bearing 
precursors.  
 
1.4 Thesis aims   
 
 This research was designed to explore the application chemical mutagenesis to both 
engineer protein activity and study natural PTMs in the context of Alzheimer’s disease. Chapter 
2 will discuss efforts to use chemical mutagenesis to enhance the anti-aggregation activity of a 
nascently functional in silico designed single-domain antibody for Ab42. This consists of the 
investigation of the properties of Dha at relevant sites of the protein with the overall aim to 
provide a new route to mature antibody activity in a rational manner similar to structure activity 
relationship (SAR) studies conducted routinely on small molecules. With the rapidly expanding 
repertoire of reactions for site-selective protein modification, we believe this field is ripe for 
the expansion of its applications to more ambitious purposes such as the one above.  
Chapter 3 will focus on the exploration of the use of chemical mutagenesis to provide 
easy access to diverse tau PTMs. The main goal is to establish protocols for the efficient and 
homogenous installation of functional and disease relevant PTMs and validate their 






































and with the accuracy of PTM mimics installed via chemical mutagenesis verified for many 
proteins, we believe that Tau research is poised to benefit greatly from this accurate and simple 
approach. The overall findings and implications will be discussed in Chapter 4 along with 
















Chapter 2: Systematic anti-aggregation enhancement 
of an Aß42 single-domain antibody through chemical 
mutagenesis  
 
2.1 Introduction  
 
2.1.1. Chemical activity maturation of proteins  
 
 Small-molecule (SM) drug discovery has very different but powerful methods for 
maturing biological activity of starting candidates when compared to antibodies. With the 
synthetic power of modern medicinal chemistry, initial SM hits can have various aspects of 
their biological activity matured atom by atom through structure activity relationship (SAR) 
studies. SAR studies can be applied to increase the potency of SMs, improve their solubility, 
enhance bioavailability, and reduce off-target effects166.  Replicating the accuracy and 
efficiency of SM SAR studies with proteins would be highly desirable, as current methods of 
directed evolution and rational mutagenesis typically lead to trade-offs of potency and stability 
(or vice-versa), especially when the target is aggregation prone116. To truly replicate the power 
of SAR studies for proteins, the limited chemical diversity of the canonical proteinogenic 
amino acids must be overcome. Unsurprisingly, genetic code expansion technology has been 
explored to address this. Schultz and co-workers carried out 4 different phage display 
campaigns against the same target (HIV protein gp120) each with a different 21st amino acid 
to expand the chemical space167. This work did indeed find that the candidate with the highest 
affinity for gp120 contained a sulfotyrosine residue in the VH CDR3 loop of the scFv. However, 
this approach is limited by both the fact that the genetic code expansion can only increase the 
chemical lexicon one amino acid at a time and that it inevitably relied on a randomised 
evolutionary process. To efficiently perform a SAR study, ideally there would be a post-
expression system for the facile and rapid expansion of the chemical space at key residues.  
 In this spirit, Berry and co-workers have utilised Dha as a synthetically versatile 
precursor to enhance enzyme activity and specificity168. Within the active site of the 
promiscuous aldolase N-acetylneuraminic lyase (NAL), the researchers screened 13 non-
canonical side chains at 12 different positions within the active site accessed through thia-
Michael additions at Dha placed at the various sites. This work identified that one chemical 
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mutant (F190-2,3-dihydroxypropyl cysteine) enhanced the kcat of NAL for a specific substrate 
pair 10-fold over any natural amino acid. This application of chemical mutagenesis for protein 
engineering represents an exciting development in the field and could enable catalytic functions 
not found in nature. For reasons discussed above, antibodies represent a very attractive next 
target for the application of chemical activity maturation. To this end, this chapter will explore 
the various chemistries available for chemical mutagenesis for a rationally designed single-
domain antibody against the N-terminus of Ab42 with nascent anti-aggregation activity with 
the aim to find hits that will improve this activity.  
 
2.1.2. Chapter aims  
 
 While affinity maturation of antibodies can be accomplished through directed evolution 
methods, enhancing more complex biological functions is difficult to accurately accomplish 
using these techniques. These functions include creating agonists and antagonists for signalling 
pathways through membrane protein engagement, inhibiting proteins crucial to the 
pathogenesis of viruses and bacteria through specific epitope engagement, as well as the 
inhibition of protein aggregation. Simply binding an immobilised target in these contexts does 
not necessarily impart the desired function. Therefore, after traditional display methods each 
candidate needs to be screened in a subsequent functional assay, which is time-consuming, 
tedious and costly. The overarching aim of this chapter is to explore if chemical mutagenesis 
can be an efficient avenue for the accurate functional maturation of an antibody candidate 
through a SAR like approach (Figure 2.2). The starting single-domain antibody contains a 
rationally designed peptide through the cascade method described in section 1.2.4 grafted into 
a human single domain VH scaffold containing thermally stabilising mutations to encourage 
fidelity through the reaction sequences116 (termed DesAB-Ab3-9). This single-domain antibody 
was chosen as our initial construct because of its starting inhibitory activity (Figure 2.18a,b). 
DesAB-Ab3-9 inhibits the primary and secondary nucleation pathways to a nearly equal extent. 
Therefore, we were curious to determine if an activity maturation campaign would enhance the 
inhibition of both pathways simultaneously or if one would be preferred over the other. A 
previous graduate student had also attempted conventional phage-display techniques on this 
antibody, which only yielded candidates with grossly compromised thermal stability. Within 
this chapter, firstly the chemistry to facilitate Dha mediated chemical mutagenesis will be 
explored along the CDR3 loop screening for amenable strategies, positions and conditions. 
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Then a first panel of diverse chemical mutants will have their desired activity investigated in a 
thioflavin-T (ThT) Ab42 anti-aggregation screen. Following the principles of SAR studies, an 
initial chemical mutant hit will then be further derivatised and characterised. Some of the 
chemistry of this project was done with assistance from Robertinah Rakoto, an Erasmus student 
from University of Strasbourg, from February 2018 to April 2018.  
 
 
Figure 2.1 SM SAR and SAR on an antibody binding loop. Illustration of the consequences 
of chemical modifications revealed through a SAR on an oxazolidinone antibiotic compared to 
the planned SAR study on an antibody binding loop.  
 
2.2 Results   
2.2.1. Cloning and purification of DesAB-Ab3-9 and the CDR3 loop cysteine mutants 
 
 In order to introduce Dha into a protein, a precursor amino acid must be decided upon 
that can be chemically converted to Dha. As discussed in section 1.3.4, cysteine represents a 
very attractive candidate for this purpose as it can be incorporated through conventional site-
directed mutagenesis, and in the case of DesAB-Ab3-9, there are only two native cysteines that 
are engaged in a disulphide bond within the interior of the protein. The starting thermostable 
DesAB-Ab3-9 DNA sequence was in a pRSET-B vector with a cleavable hexa-histidine tag to 
facilitate purification. To introduce cysteine mutants into the CDR3 loop site-directed 
mutagenesis was carried out at described in ref [169] (see Chapter 5 Materials and Methods). 
The method utilises efficient partially overlapping mutagenic primers that were designed to 
promote primer-template annealing, eliminate primer dimerization and permit newly 
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synthesised DNA to be used as a template. This approach facilitated the efficient creation of 
the cysteine mutants along the 7-residue CDR3 loop (H136C, E137C, T138C, L139C, T140C, 
L141C, and R142C).  
 With the cysteine mutant plasmids in hand the panel of proteins were then transformed 
into BL21 (DE3) Gold cells and expressed and purified according to a standard protocol (see 
Chapter 5 Materials and Methods). Briefly, bacterial cultures were grown to an OD600 nm of 
0.6 and then expression was induced by the addition of 1 mM IPTG. The cultures were left to 
express overnight at 28 oC and then lysed via sonication. The antibodies were initially purified 
from the lysate by immobilised metal affinity chromatography using Ni-NTA beads and then 
further purified by size exclusion chromatography (SEC) (Figure 2.3a-c). This protocol 
produced each mutant in excellent yield and purity (Figure 2.2c).  
 
a     b    c 
 
Figure 2.2. Purification of DesAB-Ab3-9 mutants. (a) Representative SDS-PAGE gel for 
various elution fractions from the Ni-NTA resin for DesAB-Ab3-9 (E137C), using no reducing 
agent shows the formation of a population of dimerised protein. (b) Chromatogram of a 
representative SEC run of DesAB-Ab3-9 (E137C), fractions under the black bar were collected 
and pooled. (c) SDS-PAGE under reducing conditions of a DesAB-Ab3-9 and all the Cys 
mutants used in this study.  
 
 
2.2.2. Dha installation along the CDR3 loop  
 
 With the relevant cysteine mutants in hand the next phase was to explore the ability to 
install Dha at the various sites. As discussed in section 1.3.4, there are many potential methods 
to introduce Dha from cysteine. Chalker and co-workers had extensively explored the 
compatibility and efficiency of the established methods for installation from cysteine and found 
that a bis-alkylation elimination strategy using 2,5-dibromohexanediamide was the most 
widely useful approach159 (Figure 2.4). Crucial to the current study, the researchers had used 
this method on a disulphide containing camelid nanobody to perform a site-selective 
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glycosylation reaction and found the reaction to effectively alter the sole free cysteine without 
the need to for an organic co-solvent. Inspired by their success, we attempted similar conditions 
to install Dha mutants along the CDR3 loop of the cysteine mutants. To briefly summarize 
their approach, proteins were placed in a mildly basic buffer (usually sodium phosphate [NaPi], 
pH 8) as it is crucial to have a substantial population of thiolate anions to drive the initiation of 
the reaction. The pKa of Cys typically ranges from 8-9, therefore at pH 8, 50-10% will be in 
the thiolate state respectively, enough to drive the reaction and typically tolerated by proteins. 
The rate limiting step in the formation of Dha using 2,5-dibromohexanediamide has been 
observed to be the final elimination of the proton from the a-carbon, driving the expulsion of 
the cyclised sulphur moiety159. To encourage the completion of this final part of the reaction, 
it has been found to be crucial to run the reaction at 37 °C159.  
 To break up any dimers that may have formed after the SEC step, 100 µL aliquots of 
75 µM proteins in 20 mM NaPi (pH 8) buffer were incubated with 100 equivalents of DTT for 
30 mins at room temperature (RT) with gentle shaking. DTT was then removed by a 7 kDa 
MWCO zeba desalting column using the manufacturer’s instructions and added directly to 500 
molar equivalents of powdered DBHDA and incubated at 37 °C shaking at 500 rpm for 5 hrs. 
Aliquots of each reaction were taken after the incubation and examined by LC-MS, confirming 
the homogenous formation of Dha at all positions (Figure 2.4).  
 
 
Figure 2.3. Dha conversion along the CDR3-loop of DesAb-Aß(3-9). To a 200-500 µL 
aliquot of reduced protein (~100 µM), 500 molar equivalents of solid DBHDA was added and 
the solution was vortexed for 30 seconds and then shaken at 500 rpm at 37 °C. The reaction 
was monitored by LC-MS with time points taken at 3 or 5 h (see panels a-g below). Time points 
were taken by aliquoting 2 µL of the reaction mixture and diluting it with 18 µL of the reaction 
buffer (20 mM NaPi (pH 8)), after which 5 µL of the diluted samples were injected into the 
LC-MS. Full conversion of the starting cysteine mutant to dehydroalanine was observed at all 
sites after 3-5 h. Excess DBHDA was removed by centrifuging the samples (10 min, 10,000g, 
4 °C).  
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2.2.3. Mapping Dha reactivity with b-mercaptoethanol  
 
With Dha mutants successfully installed at each position, the reactivity of Dha at the 
various positions was evaluated to establish the most practical ones to move forward with side-
chain exploration. Most studies using Dha verify its incorporation by observing its reactivity 
with b-mercaptoethanol via LC-MS. Inspired by this standard in the field, we tracked the 
addition of b-mercaptoethanol at each position by LC-MS in order to accurately track the time 
to completion as a measure of general amenability to modification (Figure 2.3). Each Dha 
mutant at 50 µM in 20 mM NaPi (pH 8) was reacted with 1000 molar equivalents of b-
mercaptoethanol in a total final volume of 100 µL at 37 °C shaking at 500 rpm. Samples were 
removed and analysed at either 15 min or 1 hr timepoints depending on the speed of the 
reaction. This assessment revealed that while Dha incorporation at the various positions was 
rather uniform, the subsequent reactivity of Dha is heterogeneous and highly dependent on the 
local chemical environment. Some positions reached completion (>95% conversion) in <15 
min (E137Dha and L139Dha) while others took as long as 6 hours (R142Dha). While it was 
not the intention of this experiment to identify the sequence contexts that make Dha reactive 
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or not, it is possible to make some reasonable speculations from this data. The least reactive 
position (R142Dha) is directly adjacent to three successive Glu residues on its C-terminal side. 
It appears that the proximity to negatively charged residues (Glu) hinders the addition of b-
mercaptoethanol, possibly due to unfavourable electrostatic interactions for the attacking 
thiolate anion. Whatever the reason, the three most promising positions to take forward for 
further side chain exploration appeared to be E137Dha, T138Dha, and L139Dha for their 
timely modification by b-mercaptoethanol and because they represent three distinct amino acid 
types (charged, polar, and nonpolar). To completely verify that these were indeed the sites of 
modification and not the cysteines in the disulphide position, these three positions had the b-
mercaptoethanol addition mapped by tandem mass spectrometry (LC-MS/MS) that was 
gratefully performed by Dr. Mike Deery of the Department of Biochemistry at Cambridge 
(Figure 2.4). This investigation indeed verified that the b-mercaptoethanol addition occurred 
at the intended sites.  
 
 
Figure 2.4. Dha reactivity map along the CDR3-loop of DesAb-Ab(3-9). Time to completion 
for each of the Dha positions. for the full reaction time course see panels a-v below. Time 
points were taken by aliquoting 4 µL of the reaction mixture and diluting it with 16 µL of the 











































































  a                                  b                                    c 
   
Figure 2.5. LC-MS/MS spectra confirming b-mercaptoethanol addition sites. (a) MS/MS 
spectrum of the m/z 482.2 doubly charged ion of the chymotryptic peptide CAAGSHCTL from 
a protein sample containing a carbamidomethyl modification at the N-terminal cysteine residue 
and a b-mercaptoethanol modification at the cysteine residue at position 137. (b) MS/MS 
spectrum of the m/z 496.2 doubly charged ion of the chymotryptic peptide CAAGSHECL from 
a protein sample containing a carbamidomethyl modification at the N-terminal cysteine residue 
and a b-mercaptoethanol modification at the cysteine residue at position 138. (c) MS/MS 
spectrum of the m/z 597.24 doubly charged ion of the chymotryptic peptide CAAGSHETCTL 
from a protein sample containing a carbamidomethyl modification at the N-terminal cysteine 
residue and a b-mercaptoethanol modification at the cysteine residue at position 139. 
 
2.2.4. Reaction exploration at Dha: C(sp3)-C(sp3) radical mediated ligation  
 
 As mentioned previously, there are three major strategies that can be taken to 
selectively modify Dha: thia-Michael addition, aza-Michael addition, and free radical C(sp3)-
C(sp3) bond formation. While the thia-Michael addition enables access to a wide array of non-
canonical side chains thanks to the diverse catalogue of commercially available thiols, we 
wanted to explore all possible routes to enable chemical activity maturation. With the C(sp3)-
C(sp3) reaction scheme, the precursors to the chemical mutants are organic molecules 
containing either iodine or bromine at the desired site of conjugation on the small molecule. 
For the initial development of this reaction, the original investigators relied heavily on the 
conjugation of 2-iodopropane to Dha, which creates an epimeric mixture of leucine at the site 
of modification. This led us to pursue this modification first as well to see if this scheme was 
amenable to modify DesAB-Ab3-9, especially as position L139 was one of the most reactive 
sites for Dha. Note that in this section of the thesis the thermally stabilising E80K mutation 
had not been implemented yet, so masses are slightly different than in previous and future 
sections.  
 For this reaction to be possible at all, a mild free radical initiator needs to be present 
with the protein and halogen bearing precursor. Davis and co-workers found that, rather 
unexpectedly, sodium borohydride was an excellent mild source of free radicals in aqueous 
solution to catalyse the reaction163. Another important aspect of this reaction is that it should 
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be performed under inert conditions, as the presence of oxygen can lead to oxidative cleavage 
at the site of Dha. These condition guidelines led us to first attempt the modification of DesAB-
Ab3-9 (L139Dha, K80E) with 1000 molar equivalents of 2-iodopropane, with sodium 
borohydride as the radical source, and in a nitrogen glovebox after degassing overnight (Figure 
2.6a). In the morning after degassing, the protein solution was topped up with buffer to 
compensate for any evaporation, 2-iodopropane was added to the solution, and the reaction 
mixture was pipetted into a new tube containing 1 mg of NaBH4. The reaction was allowed to 
proceed for 30 min with periodic shaking. A large amount of effervescence was always 
observed. However, these conditions did not lead to modification at L139Dha (Figure 2.6b). 
While L139Dha was readily modified by b-mercaptoethanol, we thought that perhaps the 
reactivity trend for thia-Michael additions did not completely correlate with reactivity towards 
free-radical addition. Therefore, we attempted the same reaction again with the addition of 6 
M GndHCl to completely unfold the protein and encourage modification. However, this only 
led to observing a partial conversion to the undesired dialkylated product (Figure 2.6c). To see 
if the cause of these poor results was the creation of radicals by NaBH4 we performed the 
reaction under denaturing conditions with L139Dha in open air. If there is an efficient 
generation of radicals nearly all of the protein should be cleaved at Dha due to the presence of 
oxygen. However, when this was performed only partial cleavage was observed (Figure 2.6d). 
This result led us to conclude that, for unknown reasons, NaBH4 is not as efficient a radical 
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Figure 2.6. Sodium borohydride mediated free radical additions. (a) Reaction scheme for 
modifying DesAB-Ab3-9 (L139Dha, K80E) with 2-iodopropane. (b) LC-MS spectrum post-
reaction under native conditions showing no modification occurred. (c) LC-MS spectrum post-
reaction under denaturing conditions showing partial dialkylation. (d) LC-MS of the reaction 
under denaturing conditions and in the open air showing only partial cleavage.  
 
 With the negative results from using NaBH4, we turned to attempting Zinc powder as 
the free radical initiator. Zn has been used in this reaction context before165, the motivation for 
pursuing NaBH4 initially was due to the safety hazards associated with powdered Zn, which is 
highly flammable. The same modification with 2-iodopropane was attempted under identical 
inert conditions as with NaBH4, except that 1 mg of Zn powder was added as the initiator 
(Figure 2.7a). Under native conditions and in an N2 atmosphere we observed a partial 
conversion to the desired product (Figure 2.7b). Encouraged by this result, we again denatured 
the protein in the presence of 6 M GndHCl to remove any potential structural hinderances to 
modification. To our dismay, this only increased the level of modification marginally (~20% 
to ~50% of dominant peak, Figure 2.7c). We again investigated the efficiency of free-radical 
generation by performing the reaction under denaturing conditions and in the open-air (Figure 
2.7d). Under these conditions with the Zn powder we observed full cleavage of the protein and 
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an unexpected further mass shift, possibly from oxidation of a residue during the reaction due 
to the presence of excess O	•	in the reaction. From this result it is clear that Zn powder is an 
efficient source for free radicals, and there is some other unknown factor that is discouraging 
efficient modification at this site.  
These discouraging results for the C-C bond forming reaction using two different free 
radical initiators were unexpected given the reported ease and wide applicability of this 
reaction, according to the inventors165. Our difficult experience with this reaction coupled with 
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Figure 2.7. Zinc powder mediated free radical additions. (a) Reaction scheme for modifying 
DesAB-Ab3-9 (L139Dha, K80E) with 2-iodopropane. (b) LC-MS spectrum post-reaction under 
native conditions showing slight modification occurred. (c) LC-MS spectrum post-reaction 
under denaturing conditions showing similar partial alkylation as to native conditions. (d) LC-
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MS of the reaction under denaturing conditions and in the open-air showing cleavage and 
potentially further oxidation. 
 
2.2.5. Reaction exploration at Dha: Aza-Michael addition  
 
 While the C-C bond forming reaction had disappointing results, we still sought to 
pursue another possible route of modification other than thiols. A couple more recent studies 
have demonstrated that Dha can be efficiently modified with secondary amines, hydrazines, 
and hydroxylamines161,162. This reaction piqued our interest in particular as this allows 
modification by piperidine, which is easily derivatised and one of the most common 
heterocycles in small molecule drugs166. Piperidine had previously been used to modify a 
camelid nanobody, so we initially pursued conditions used in that report162. Modification was 
initially pursued for DesAB-Ab3-9 (T138Dha, K80E), as the original threonine residue was 
polar and the resulting derivatives of piperidine would be as well. Performing the reaction with 
250 molar equivalents and at room temperature yielded a homogenously modified product in 
30 mins (Figure 2.8b). However, when the structural integrity was investigated by CD it was 
observed that the reaction had denatured the protein (Figure 2.8d). With the belief that the 
denaturation was caused by the high pH of the reaction brought about by the excess piperidine, 
the reaction with only 100 molar equivalents of over 1 hour was attempted. While this led to 
homogenous conjugation (Figure 2.8c), once again the CD revealed that the protein was 
denatured (Figure 2.8d).  
 Many procedures exist to refold denatured proteins, and we were curious if we could 
rescue this piperidine mutant through such a protocol. 6 M GndHCl was added to the modified 
product after reaction with 100 molar equivalents of piperidine to completely denature the 
protein. After sitting on ice for 30 minutes, the sample was injected onto a Superdex 75 10/300 
Increase SEC column equilibrated in 20 mM NaPi buffer. This was done with the hope that the 
individual proteins would be able to safely refold on the column while the GndHCl is gradually 
diluted away as the run progresses. Checking the protein by CD after elution revealed that this 
refolding protocol worked, producing a profile largely resembling that of the starting scaffold 
(Figure 2.8d).  
 While the refolding protocol was successful, the extra labour needed makes this a rather 
cumbersome approach to conduct the side-chain exploration. With this in mind, we sought to 
solely pursue the thiol-based approach for Dha modification. However, with this refolding 
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Figure 2.8. Aza-Michael additions with piperidine. (a) Initial reaction scheme for modifying 
DesAB-Ab3-9 (T138Dha, K80E) with piperidine. (b) LC-MS spectrum of the homogenous 
product from the initial conditions. (c) LC-MS spectrum of the modified protein after dropping 
the molar equivalents of piperidine from 250 to 100 and extended the reaction time to 1 hr. (d) 
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2.2.6. Side-chain exploration and activity screening at E137Dha  
 
Dha at position 137 was one of the most reactive with b-mercaptoethanol (<15 min) 
and was at a position previously occupied by a negatively charged amino acid (glutamic acid). 
This led us to explore non-canonical side chains at this position containing negatively charged 
functional groups to see if modulating this property could lead to an activity increase. Three 
different chemical mutants were chosen to be screened: (4-nitrobenzyl)mercaptan, 2-
mercaptoethanesulfonate (MESNA), and L-cysteine (Figure 2.9a). The conditions for 
conjugation were unchanged from the b-mercaptoethanol screen (20 mM NaPi [pH 8], 37 °C, 
500 rpm) except that the reaction time was extended to an hour in case there was a variable 
reactivity amongst the attacking thiols. After 1 hr the LC-MS confirmed that all reactions had 
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Figure 2.9. E137Dha reactions. (a) Reaction scheme for side-chain exploration at E137Dha 
through thia-Michael additions and the three chemical mutants generated. (b) LC-MS data for 
E137(4-nitrobenzyl)mercaptan confirming a homogeneous conversion. (c) LC-MS data for 
E137MESNA confirming a homogeneous conversion. (d) LC-MS data for E137L-Cys 
confirming a homogeneous conversion. 
 
Before screening for activity, the structural integrity of the chemical mutants was assessed via 
CD (Figure 2.10). This confirmed that all of the mutants at position 137 displayed a high 
similarity to the starting scaffold.  
 
Figure 2.10. E137 chemical mutant’s CD profiles. CD traces of DesAB-Ab3-9 and the various 
chemical mutants at position 137. 
 
With the chemical mutants in hand and their integrity checked an activity screen was 
performed using an Ab42 anti-aggregation assay. To accurately assess the mechanism of 
inhibition, the ThT-based fluorescence of the aggregation of Ab42 under reference conditions 
is carried out alongside a serial dilution of the inhibitor in question. If the inhibitor is indeed 
E137L-Cys
Calc. desired mass: 17491 Da































active and alters the aggregation profile, these perturbations can be analysed to elucidate the 
changes in the different rate constants caused by the inhibitor83. Lyophilised recombinant Ab42 
graciously prepared by Swapan Preet and Ewa Klimont of the Centre for Misfolding Diseases. 
To prepare the Ab42 for the kinetic assays, a final SEC step was carried out after resuspending 
the lyophilised protein in 6 M guanidinium chloride in order to ensure the peptide was in its 
monomeric form at the beginning of the assay (Figure 2.11a). Using this approach, the 
chemical mutants were screened at three dilutions (1:2, 1:4 and 1:8 [antibody]:[Ab42]) in 
triplicate, with the concentration of Ab42 held constant at 1.5 µM. The modest activity of the 
starting DesAB-Ab3-9 can be seen for reference in Figure 2.11b. Unfortunately, all of the 
chemical mutants screened at position E137 ablated all anti-aggregation activity (Figure 2.11c-
e). Therefore, no further modifications were pursued at this site.  
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 b      c 
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Figure 2.11. Ab42 purification and anti-aggregation screens for E137 chemical mutants. 
(a) Chromatogram at 280 nm for the final SEC of Ab42. The fraction collected for use in the 
aggregation assays is marked by the lack bar. (b) Aggregation curves for DesAB-Ab3-9. (c) 
Aggregation curves for DesAB-Ab3-9 (E137[4-nitrobenzyl]mercaptan). (d) Aggregation curves 
for DesAB-Ab3-9(E137MESNA). (e) Aggregation curves for DesAB-Ab3-9(E137L-Cys). The 
Ab concentration for each reaction is 1.5 µM and the antibody concentration in the 1:2 
condition is 750 nM, in the 1:4 condition the concentration is 375 nM, and in the 1:8 condition 
it is 187.5 nM.  
 
 
2.2.7. Side-chain exploration and activity screening at L139Dha  
 
 Position 139 was equally reactive as 137 to the modification of Dha by b-
mercaptoethanol and was originally occupied by leucine. Therefore, we chose to explore the 
installation of a variety of non-canonical aliphatic sidechains at this position. The three initial 
aliphatic molecules pursued for conjugation were: tert-butanethiol, hexanethiol, and 1-
butanethiol (Figure 2.12a). These chemicals produce very potent noxious odours and great 
care must be taken when handling them outside of a fume hood. While b-mercaptoethanol was 
capable of fully conjugating to L138Dha in less than 15 mins, the aliphatic thiols took 
considerably longer to reach completion. After reacting for 8 hrs, all three chemical mutants 
had only achieved partial conversion to the desired product (Figure 2.12b). To achieve full 
conversions the reaction time had to be extended to 12 hrs (Figure 2.12c-e). The discrepancy 
in the reactivity of the aliphatic thiols compared to b-mercaptoethanol could arise from the 
different miscibility profiles of the thiols. The volatility of the aliphatic thiols also likely meant 
that less than 1000x molar equivalents was added to the reaction. If these chemical mutations 
were to be attempted on a less thermally stable protein, the addition of an organic co-solvent 
(such as N,N-dimethylformamide [DMF]) may speed up the reaction. 
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Natural amino acid Non-canonical amino acids
L139Butanethiol - Partial completion at 8 hrs
Calc. starting mass: 17383 Da
Calc. desired mass: 17476 Da











Calc. desired mass: 17476 Da
Obs. mass: 17476 Da
L139Hexanethiol
Calc. desired mass: 17502 Da







Figure 2.12. L139Dha reactions. (a) Reaction scheme for side-chain exploration at L139Dha 
through thia-Michael additions and the three chemical mutants generated. (b) Representative 
timepoint after reacting for 8 hrs for the conjugation of 1-butanethiol to L139Dha, the other 
two aliphatic thiols had comparable conversions at this time. (c) LC-MS data for L139Tert-
butanethiol confirming a homogeneous conversion. (d) LC-MS data for L139Hexanethiol 




 Just as with the E137 chemical mutants, the aliphatic L139 mutants had their structural 
integrity assessed by CD. This confirmed that even after the 12-hr reaction time, the chemical 
mutants were still folded correctly and could then be screened for their anti-aggregation activity 
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Figure 2.13. L139 chemical mutant’s CD profiles. CD traces of DesAB-Ab3-9 and the various 
chemical mutants at position 139. 
 
 These three chemical mutants had their anti-aggregation activity assessed in the same 
manner as the E137 mutants. Disappointingly, none of these larger aliphatic groups had any 
significant benefit for the anti-aggregation activity (Figure 2.14a-c). Therefore, no further 
mutants were pursued at this position.  
 
a    b    c 
   
Figure 2.14. Ab42 anti-aggregation screens for L139 chemical mutants. (a) Aggregation 
curves for DesAB-Ab3-9 (L139-1-butanethiol). (b) Aggregation curves for DesAB-Ab3-
9(L139Tert-butanethiol). (c) Aggregation curves for DesAB-Ab3-9(L139Cyclohexanethiol). 
The Ab concentration for each reaction is 1.5 µM and the antibody concentration in the 1:2 
condition is 750 nM, in the 1:4 condition the concentration is 375 nM, and in the 1:8 condition 
it is 187.5 nM. 
 
2.2.8. Initial side-chain exploration and activity screening at T138Dha  
 
 Dha at position T138 was the least reactive with b-mercaptoethanol compared to the 
other two positions chosen for sidechain exploration. With threonine being the original 















































































more polar groups, and altering the heteroatom. To achieve these alterations, we conjugated b-
mercaptoethanol, 1-thioglycerol, and cysteamine to T138Dha. Since the other two thiols were 
very similar in properties to b-mercaptoethanol, the same reaction conditions and time that was 
initially determined in the reactivity screen was used for each reaction (Figure 2.15a). All 
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Calc. desired mass: 17475 Da
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Figure 2.15. T138Dha reactions. (a) Reaction scheme for initial side-chain exploration at 
T138Dha through thia-Michael additions and the three chemical mutants generated. (b) LC-
MS data for T138b-mercaptoethanol confirming a homogeneous conversion. (d) LC-MS data 
for T138-1-thioglycerol confirming a homogeneous conversion. (e) LC-MS data for 
T138Cysteamine confirming a homogeneous conversion.  
 
 Just as with the chemical mutants at E137 and L139, the T138 mutants had their 
structural integrity confirmed by CD. Each mutant had a CD profile comparable to that of 




Figure 2.16. T138 chemical mutant’s CD profiles. CD traces of DesAB-Ab3-9 and the various 
chemical mutants at position T138. 
Calc. desired mass: 17474 Da





























 The T138 chemical mutants had their anti-aggregation activity screened in the same 
manner as the previous chemical mutants. This revealed that while the b-mercaptoethanol and 
1-thioglycerol chemical mutants ablated activity, the cysteamine mutant displayed a dose-
dependent alteration of the aggregation profile (Figure 2.17a-d).  
 
 a     b 
  
 c      
 
Figure 2.17. Ab42 anti-aggregation screens for T138 chemical mutants. (a) Aggregation 
curves for DesAB-Ab3-9 (T138b-mercaptoethanol). (b) Aggregation curves for DesAB-Ab3-9 
(T138-1-thioglycerol). (c) Aggregation curves for DesAB-Ab3-9 (T138Cysteamine). The Ab 
concentration for each reaction is 1.5 µM and the antibody concentration in the 1:2 condition 
is 750 nM, in the 1:4 condition the concentration is 375 nM, and in the 1:8 condition it is 187.5 
nM. 
 
 To confirm that the cysteamine mutation at T138 did indeed enhance the anti-
aggregation activity, we sought to elucidate the effect of the mutation on the microscopic steps 
of the aggregation process. Using the integrated kinetic rate laws described in Section 1.1.5, 
we determined the antibody’s effect on the global parameters k+kn and k+k2 (where again k+ is 
the elongation rate, kn is the nucleation rate, and k2 is the secondary nucleation rate). Each curve 
within the dilution series of both DesAB-Ab3-9 and DesAB-Ab3-9(T138Cysteamine) was fit 







































well by the model (Figure 2.18a & c) and revealed that the cysteamine mutation does indeed 
enhance the inhibition of the primary nucleation reaction (Figure 2.18b & d).  
 a      b 
 
 c      d 
 
Figure 2.18. DesAB-Ab3-9(T138Cysteamine) has enhanced inhibition of primary 
nucleation. (a) Normalised aggregation curves for the dilution series of DesAB-Ab3-9 (open 
coloured circles) and fits of the data using the integrated rate laws (solid blue lines). (b) Plot of 
the individual global aggregation parameters for each of the DesAB-Ab3-9 dilutions relative to 
the Ab alone parameters. (c) Normalised aggregation curves for the dilution series of DesAB-
Ab3-9 (T138Cysteamine) (open coloured circles) and fits of the data using the integrated rate 
laws (solid blue lines). (d) Plot of the individual global aggregation parameters for each of the 
DesAB-Ab3-9(T138Cysteamine) dilutions relative to the Ab alone parameters, red shaded 
circle highlights the potentiated reduction of the k+kn parameter. 
 
 After confirming the activity enhancement with the kinetic model, a few more 
exploratory controls had to be conducted. To investigate if this potentiation by cysteamine is 
dependent on the site of installation we created chemical mutants with it conjugated to both 
E137 and L139 positions using the same reaction conditions as for T138. Cysteamine was 
efficiently installed at both sites and created homogenous products (Figure 2.19a & b). 
Screening these two mutants for their aggregation activity revealed that neither recapitulate the 
Starting activity of DesAB-Aß3-9
Activity of DesAB-Aß3-9 (T138Cysteamine)
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activity of the mutation at position T138, confirming that the potentiation by the cysteamine 
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Figure 2.19. Creation and investigation cysteamine chemical mutants at positions E137 
and L139. (a, b) LC-MS spectrums confirming the clean production of both DesAB-Ab3-9 
(E137Cysteamine) and (L139Cysteamine) chemical mutants, respectively. (c, d) Anti-
aggregation screens for cysteamine mutants at both positions, confirming neither recapitulate 
the activity observed at position T138. The Ab concentration for each reaction is 1.5 µM and 
the antibody concentration in the 1:2 condition is 750 nM, in the 1:4 condition the concentration 
is 375 nM, and in the 1:8 condition it is 187.5 nM. 
 
 Of the canonical amino acids, the cysteamine chemical mutant is most similar to lysine. 
The only differences are the thioether linkage at the g position and the creation of a mixture of 







































epimers that is inherent when using Dha (see section 1.3.4). With this high degree of similarity, 
we were curious as to if the chemical installation of cysteamine was necessary to enhance 
DesAB-Ab3-9’s activity or if a simple genetic mutation to lysine at position 138 would also 
potentiate activity. DesAB-Ab3-9(T138K) was thusly created using conventional site directed 
mutagenesis and purified in the same manner as previously described, yielding the expected 
product (Figure 2.20a). To account for any changes that may have occurred during the reaction 
process, the T138K mutant was subjected to the same prolonged incubations at 37 oC in the 
same buffers that were used to generate T138Cysteamine. At the end of this, the CD profile of 
T138K was very similar to both DesAB-Ab3-9 and T138Cysteamine (Figure 2.20b). However, 
the anti-aggregation screen with T138K revealed that it had almost no activity (Figure 2.20c). 
This finding could be a result of the fact that addition at Dha creates an epimeric mixture of D 
and L sidechains, or possibly from some subtle conformational changes the CDR3 undergoes 
during the transformations. Regardless of the reasons, in summary cysteamine proved to be the 
first potentiating chemical mutant in the initial screen at the three positions of the CDR3 loop. 
Its enhancing effect is position dependent and cannot be recapitulated by the most similar 
canonical amino acid. Serendipitously, the terminal amine of cysteamine provides an excellent 








b       c 
  
Figure 2.20. Creation and characterisation of DesAB-Ab3-9(T138K). (a) LC-MS 
confirming the desired mass. (b) CD spectrums of T138K and T138Cysteamine compared to 
the starting antibody’s profile, verifying they have similar structures. (c) Ab anti-aggregation 
screen for T138K. The Ab concentration for each reaction is 1.5 µM and the antibody 
concentration in the 1:2 condition is 750 nM, in the 1:4 condition the concentration is 375 nM, 
and in the 1:8 condition it is 187.5 nM. 
 
2.2.9. Derivatisation of T138Cysteamine   
 
 Small molecule SAR studies typically pursue multiple rounds of derivatisation before 
the desired biological activity is achieved. The terminal amine of our cysteamine hit provides 
an ideal point for the further exploration of subtle chemical alterations to further potentiate the 
anti-aggregation activity of DesAB-Ab3-9. Based on what derivatives were commercially 
available or could be easily synthesized, we created a panel of chemical mutants that had a 
range of physiochemical changes based on the cysteamine scaffold (Figure 2.21a). These 
changes included altering the charge of the side chain, such as removing it through the addition 
of an acetyl group, inverting it with a sulphate group, and fixing it through tri-methylation. 
Other changes included dimethylation and the addition of a larger heterocycle. The only desired 
derivative that was not commercially available was N,N,N-trimethylcysteamine, which had to 
by synthesised according to an established protocol (see Materials and Methods). All of these 
derivatives achieved homogenous conjugation to T138Dha under the same conditions used for 

















































































Calc. desired mass: 17539 Da









Calc. desired mass: 17517 Da














Figure 2.21. Cysteamine derivative reactions. (a) Panel of cysteamine derivatives for activity 
screening. (b) LC-MS data for T138MESNA confirming a homogeneous conversion. (c) LC-
Calc. desired mass: 17504 Da
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Calc. desired mass: 17545 Da








MS data for T138Acetyl-cysteamine confirming a homogeneous conversion. (d) LC-MS data 
for T138Captamine confirming a homogeneous conversion. (e) LC-MS data for T138N,N,N-
trimethylcysteamine confirming a homogeneous conversion. (f) LC-MS data for T138-4-
morpholineethanethiol confirming a homogeneous conversion.  
 
 As with all of the previous chemical mutants, these cysteamine derivates had their 
structural integrity assessed by CD. This revealed that once again all of the chemical mutants 
displayed a similar profile to the starting scaffold (Figure 2.22).  
 
 
Figure 2.22. Cysteamine derivative chemical mutant’s CD profiles. CD traces of DesAB-
Ab3-9 and the various cysteamine derivatised chemical mutants at position T138. 
 
 The derivatives were then screened for their anti-aggregation activity in the same 
manner as previously described. This second screen at position 138 found that T138Captamine 
had an even more potent inhibition of Ab aggregation compared to the starting activity and to 
T138Cysteamine (Figure 2.23a-e). 
 







































































Figure 2.23. T138Captamine has an enhanced inhibition of aggregation. (a-e) Aggregation 
curves for cysteamine derivatives at position T138. DesAB-Ab3-9 (T138Captamine) in panel 
(c) is the only one that displays a significant improvement compared to T138Cysteamine. The 
Ab concentration for each reaction is 1.5 µM and the antibody concentration in the 1:2 
condition is 750 nM, in the 1:4 condition the concentration is 375 nM, and in the 1:8 condition 
it is 187.5 nM. 
 
 To confirm which microscopic step in the aggregation reaction the captamine derivative 
enhanced a kinetic analysis was once again performed. This analysis confirmed that the 
captamine mutation built upon the previous potentiation of the primary nucleation reaction that 
cysteamine had over the starting construct (Figure 2.24a,b). When the primary nucleation rates 
of the 1:2 dilutions of the starting DesAB-Ab3-9 and the T138Captamine chemical mutant are 
directly compared it can be seen that there is a nearly 5-order of magnitude decrease in the 
nucleation rate global parameter with this single amino-acid change (Figure 2.24c). This 5-
order of magnitude decrease in the rate constant, however, only leads to a ~10-fold retardation 
of the half-life at the 1:2 condition. This is due to the unperturbed contributions of the 
secondary nucleation pathways. To compare this potency to the activity of different anti-
aggregation agents, one parameter to look at is the inhibitory concentration that yields a 50% 
increase in the time to reach peak fibril mass (known as the KIC50). A recent development 
campaign to yield small molecule inhibitors of Ab aggregation produced candidates 































































approaching a KIC50 of 1 µM89. Our lowest tested concentration of 187.5 nM for DesAB-Ab3-
9 (T138Captamine) yielded a ~200% increase in time to peak fibril mass. Therefore, it is likely 
that the KIC50 is in the range of 100-150 nM; nearly 10 times the potency of the best small 
molecules. However, more detailed experiments in the lower concentration ranges will need to 
be conducted to definitively determine the KIC50. 
At this point, the primary nucleation parameter that has been used for comparison has 
not been decoupled from the elongation rate (kNk+, where k+ is the elongation rate). To be sure 
that the majority of the inhibition can be directly attributed to the inhibition of primary 
nucleation, rather than elongation, we performed an inhibition screen where elongation is the 
dominant form of fibril growth. This was achieved by performing the aggregation reaction in 
the presence of 30% (by monomer concentration) preformed Ab fibrils. With this high 
concentration of fibrils, the contribution of primary and secondary nucleation to fibril growth 
can be considered negligible85. So, in this case with 1.5 µM Ab monomer, 450 nM fibrils were 
added, and the antibodies were added in a 1:1 ratio to monomer. This revealed that the 
T138Captamine chemical mutant had only a slight effect on inhibiting fibril elongation 
compared to the starting scaffold, confirming that most of the inhibitory activity can be directly 
attributed to the inhibition of primary nucleation (Figure 2.24d).  
 








c      d 
 
 
Figure 2.24 Kinetic characterisation of DesAB-Ab3-9(T138Captamine). (a) Fits of the 
kinetic model to the dilution series of the anti-aggregation screen. (b) Decoupled global 
parameters for the primary and secondary nucleation rates, showing that the captamine 
mutation further potentiates the inhibition of primary nucleation. (c) Comparison of the 
apparent primary nucleation rates for the 1:2 antibody dilutions of DesAB-Ab3-9 (black) and 
T138Captamine (teal). (d) Screen for the inhibition of fibril elongation by DesAB-Ab3-9 (red) 
and T138Captamine (teal). 
 
 We then characterized the binding of DesAB-Ab(3-9)(T138Captamine) and the starting 
construct to C-terminally immobilized monomeric Ab42 by biolayer interferometry (BLI). The 
C-terminally biotinylated Ab was loaded onto streptavidin BLI tips overnight at 5 oC while 
control streptavidin tips were coated with biocytin. The association and dissociation signals of 
each the antibodies to the control tips was subtracted from their respective signals produced by 
the Ab coated tips to account for any non-specific binding. The results revealed that the two 
antibodies bound monomeric Ab42 under these conditions in a very similar manner (Figure 
2.25a). We note that, since it is difficult to apply BLI to accurately quantify the binding to 
Ab42, in particular because immobilizing Ab42 drastically alters the structural ensemble that 
this disordered peptide adopts compared to its free state in solution, these data do not 
conclusively explain the mechanism behind the enhanced inhibition, which could also be 
brought about by the enhanced association with primary oligomers or other aggregated species.  
 Finally, we measured the conformational stability of our potentiated single-domain 
antibody DesAb-Ab(3-9)(T138captamine) by means of thermal denaturation. Our results show 
that the melting temperature is identical to that of DesAb-Ab(3-9) within the measurement error, 
and the melting profiles essentially overlap (Figure 2.25b). This observation is particularly 



















interesting because through conventional methods of activity maturation, there is often a 
significant trade-off between stability and activity when comparing the starting and end 
constructs, a phenomenon that has been reported to be particularly extreme in the case of 
aggregation-prone antigens like Ab116. The single uniform melting curve also supports the 
integrity of the disulfide bond in both the chemical mutant and starting single-domain antibody, 
as a reduced population yields a multistep melting curve. 
a           b 
 
Figure 2.25 BLI and thermal stability comparisons. (a) BLI association and dissociation 
curves for DesAB- Ab3-9 (black, orange fit) and T138Captamine (teal, red fit) to C-terminally 
immobilised Ab42. (b) Thermal denaturation curves measured by CD at 207 nM for DesAB- 
Ab3-9 (black) and T138Captamine (teal).  
 
2.3 Conclusion  
 
 In this chapter we investigated if chemical mutagenesis could be used to conduct a 
structure activity relationship beyond the 20 canonical amino acids on a single-domain 
antibody. Our starting antibody had an initially nascent designed activity to inhibit the 
aggregation of the Ab peptide. The first step to approach this project was to install the 
synthetically versatile non-canonical amino acid Dha at each position along the CDR3 loop. 
This was accomplished by initially installing cysteine at each position in the loop by genetic 
means then eliminating the free thiol through a bis-alkylation-elimination reaction to Dha post-
expression. Encouragingly for this approach, the conversion to Dha was uniformly successful 
along the loop, potentially meaning most CDR sequences could be amenable to this chemical 
activity maturation approach. The next course of action was to screen Dha at each position for 
its own accessibility for modification. To investigate this, a reactivity screen was performed 
with the benchmark reagent b-mercaptoethanol where the time to completion was closely 
monitored by LC-MS. This experiment revealed that the local chemical environment 
surrounding Dha has a powerful influence over its reactivity, with some positions reaching 





















most accessible sites for side-chain exploration, we attempted two other routes to modification 
other than thia-Michael additions: free radical based C-C bond formation and aza-Michael 
ligation. However, neither of these two approaches were pursued after an initial investigation 
due to poor reaction efficiency and detrimental effects on the protein structure, respectively. 
Using solely thiol-based reagents, initial side-chain exploration was conducted at the 3 sites 
with diverse functional groups. Subsequent activity screening for the enhanced inhibition of 
Ab aggregation revealed that one chemical mutant (T138Cysteamine) had improved inhibition 
of the primary nucleation reaction. In the spirit of small molecule SAR studies, the initial 
cysteamine “hit” was diversified with subtle to dramatic chemical changes to try to drive the 
potency even more. This identified that the addition of two methyl groups to the terminal amine 
further drove the potency for inhibiting the primary nucleation reaction, ending up 5 orders of 
magnitude more potent than the starting sequence. Importantly, this approach of chemical 
activity maturation led to no compromise in the stability of the protein. Activity and stability 
trade-offs are commonly encountered in traditional directed evolution campaigns112, so this 
type of hyper-specific chemical modification to single amino acids to drive activity may be a 





















Chapter 3: Facile installation of tau PTM mimetics 
via chemical mutagenesis  
 
3.1 Introduction  
 
3.1.1. Tau PTMs and their study   
 
 Many crucial roles for tau in neuronal function are becoming recognized beyond 
regulating microtubule dynamics64. This expanding diversity of function is no doubt a 
consequence of the incredible diversity and shear number of PTMs that tau has been observed 
to undergo83. A plethora of approaches have been taken to accurately study the effects of tau 
PTMs. Early on in the literature, the effects of phosphorylation at specific sites was investigated 
by genetic means through the mutation of Ser/Thr residues to Glu/Asp to mimic the 
physiochemical changes brought about by phosphorylation170. While this approach proved 
initially useful, the terminal carboxylic acid of glutamic or aspartic acid is ultimately a poor 
approximation of phosphorylation for a number of reasons. The pKa value for the carboxylate 
side chains are ~ 4 while the first pKa value for phosphate is ~ 2 and the second ~ 6. This means 
that at physiological pH a Glu/Asp residue will only have a -1 charge while phosphate will be 
-2. The geometry is also inconsistent, with the carboxylate group in a trigonal planar structure 
while phosphate groups are tetrahedral. Similar physiochemical discrepancies can also be listed 
for genetic mimics of other PTMs like using Gln/Asn to mimic acetylation. Purified tau can be 
phosphorylated in vitro when combined with specific kinases under appropriate conditions, 
however, this approach usually leads to a heterogeneous mixture of sites being modified171,172. 
Therefore, making it difficult to accurately assign effects to single specific modifications. 
Enzymatic modification in vitro is also only possible for certain observed modification of tau. 
These inescapable short comings of genetic approaches have led to the development of more 
sophisticated approaches to accurately study protein PTMs as a whole.  
 A particular approach of note for tau is a semi-synthesis protocol developed by Lashuel 
and co-workers used to site-specifically incorporate exact PTMs into tau173 (Figure 3.1). This 
is a particularly powerful approach as it allows more than 1 PTM to be incorporated at a time 
and can introduce disparate and non-enzymatic PTMs altogether. The protocol calls for a large 
N-terminal fragment of tau to be recombinantly expressed and purified from bacteria, then 
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shorter 50-60 amino acid fragments of the C-terminus are created through solid phase peptide 
synthesis and combined via native chemical ligation, taking advantage of the two endogenous 
Cys residues. While the power of this approach is clear, this protocol can only be carried out 
by an experienced synthetic chemist specialising in peptide chemistry, a type of person not 
readily available to most labs interested in studying PTM effects on tau. It is therefore desirable 
to develop more universally friendly approaches to generate site-specific PTMs on tau.  
 Here chemical mutagenesis can again prove its utility. Some of the earliest applications 
of chemical mutagenesis in its resurgence were to accurately study PTMs. Different approaches 
of chemical mutagenesis have been used to study kinase activation, histone modifications, and 
incredibly complex glycosylation patterns to list a few examples163,160,174. From the successes 
of these diverse projects, tau appears ripe for the application of this technique.  
 
 
Figure 3.1. Semi-synthesis of Tau bearing PTMs. (a) Sequence of tau broken down into 
regions for semi-synthesis. (b) Semi-synthesis scheme. Figure adapted with permission from 
reference [173].  
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3.1.2. Chapter aims  
 
 The overall aim of this chapter will be to assess the amenability of tau to create several 
PTMs at different sites along this large protein. Since phosphorylation is the most common and 
well-studied modification of tau, three disparate sites of known phosphorylation will be 
explored as well as a dual phosphorylation. Two of these sites, S262 and S356, have been 
previously established to significantly impair tubulin polymerisation activity171,175. These two 
sites will serve to verify the accuracy of the PTM mimetics installed via Dha. These sites will 
also be the two pursued in the dual phosphorylation reaction. The other site, S199 in the proline 
rich domain (PRD), has been shown to be a biomarker for AD174,175, but has not had the actual 
effects of phosphorylation on the protein behaviour explored. If the S262 and S356 positions 
verify the accuracy of this approach, to our knowledge this work will constitute the first 
characterisation of phospho-S199 on tau function. The growing importance of modifications 
other than phosphorylation on Tau cannot be ignored. To this end, we will also look to install 
lysine acetylation and dimethylation mimetics at K311, located in one of the most 
amyloidogenic portions of the protein68. The acetylation mimic will also serve to verify the 
accuracy of this approach, as Lashuel and co-workers have characterised acetylation at K280 
via their semi-synthesis approach, which is located in a nearly identical repeat earlier on in the 
protein sequence173. Dimethylation on K311, however, has not had its effects explored yet and 
has only been relatively recently characterised in proteomics experiments from tissue 
samples83. The first aim for all of these positions and modifications will be to purify the 
respective cysteine mutants, second to find an approach to efficiently convert these to Dha, 
then to develop the reactions for the final modifications, and lastly to perform an initial 
characterisation of these PTMs by assessing their effects on the tubulin polymerisation activity 
of tau. Some of the work in this chapter was done with the assistance of Ross Taylor during 
his BBSRC rotation in the Vendruscolo lab from October 2019 to December 2019.  
 
3.2 Results  
 
3.2.1. Tau mutagenesis, expression and purification  
 
 Recombinant 2N4R tau was expressed in a similar manner to previously established178. 
The original pet29b vector containing the 2N4R (C291S & C322S) sequence was gratefully 
gifted by the Klenerman lab. Site-directed mutagenesis was carried out on this plasmid in the 
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same manner as the antibodies in chapter 3 to create the desired cysteine mutants (S199C, 
S262C, S356C, S262C & S356C, and K311C) (see Materials and Methods)169. Once the 
sequences were verified, the plasmids were transformed into BL21 Gold DE3 cells for 
expression. The various mutants were expressed in 6x1 L cultures overnight at 18 oC after 
induction with IPTG. The bacteria were then harvested by centrifugation and the pelleted cells 
were resuspended in 50 mM MES (pH 6.5), 5 mM DTT, 0.1 mM PMSF and lysed via 
sonication. The lysed solution was then centrifuged again, and the supernatant was collected 
and kept. After the addition of RNAse and DNAse, the supernatant was passed through a filter 
before undergoing cation exchange chromatography using a Hitrap CaptoS column. All the 
fractions in the highest UV signal at the end of the salt gradient were collected and assessed by 
SDS-PAGE for the presence of Tau (Figure 3.2a,b). All fractions containing Tau were pooled 
and precipitated on ice overnight by the addition of 20% (w/v) ammonium sulphate. The 
precipitated solutions were pelleted via centrifugation and then resuspended in a small amount 
of SSPE buffer containing 5 mM DTT, this solution was then run on a Superdex 200 Increase 
10/300 GL SEC column to isolate the pure tau, fractions under the appropriate UV signal were 
again assessed by SDS-PAGE and only the purest fraction was kept for experiments (Figure 
3.2c-i). All variants were expressed and purified in good yield.  
 








c           d 
 
Figure 3.2. Tau purification. (a) Representative chromatogram from the cation exchange step 
of 2N4R tau, black bar indicated the collected fractions. (b) Image of a representative SDS-
PAGE of the collected fractions from the cation exchange (along with the pellet and early on 
fractions), yellow arrow points to tau. (c) Chromatogram from a representative SEC of 
precipitated tau, black bar again indicates collected fractions. (d) SDS-PAGE of the fractions 
collected from two different SEC runs (WT Tau and S356C Tau, respectively), fractions with 
the yellow box indicate those kept for experiments.   
 
 
3.2.2. Dha formation on Tau   
 
 The same approach to Dha formation that was taken in Chapter 2 was also applied to 
tau. The first cysteine variant that was purified was S199C, and so the reaction with DBHDA 
was first attempted with this protein. S199C was buffer exchanged into 20 mM NaPi (pH 8) 
and then 500x molar equivalents of DBHDA was added and then allowed to react at 37 oC and 
500 rpm, exactly like the antibodies. Unfortunately, checking the reaction by LC-MS revealed 
that even after very extensive incubations of 24 hrs the protein was stuck at a stable 
intermediate along the pathway to forming Dha (Figure 3.3). These extended incubations also 
led to very noisy spectra. From these preliminary reactions, it was clear that a more efficient 
approach to forming Dha on tau is needed. This also serves to highlight that any chemical 
mutagenesis approach must be heavily tailored to the protein of interest, which is not 




Figure 3.3. Attempted Dha formation on Tau via DBHDA at 24hrs. LC-MS spectrum of 
the reaction of S199C with DBHDA after 24 hrs using the same conditions as the antibodies. 
It can be seen that the reaction has stalled at one of the intermediates on the way to Dha.  
 
 Luckily for us, a more efficient bis-alkylation elimination reagent has recently been 
developed179. The reagent, methyl 2,5-dibromopentanoate (MDBP) (Figure 3.4a), is a slightly 
water miscible liquid that has a much-enhanced rate of both addition to cysteine and subsequent 
elimination compared to DBHDA162. This molecule was engineered to allow for the conversion 
of multiple Cys residues to Dha on peptides, avoiding the unwanted side product of an 
intramolecular addition of an unconverted Cys to Dha elsewhere on the protein, which will be 
very important for the dual modification of the S262C & S356C mutant. Using the same buffer 
and conditions as previously for DBHDA, 50 molar equivalents of MDBP was added to each 
of the mutants and allowed to react at 37 oC shaking at 500 rpm overnight. Checking the 
reactions by LC-MS in the morning confirmed that the MDBP regent afforded full conversions 
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Figure 3.4. Dha formation on Tau with MDBP. (a) Reaction scheme for Cys containing tau 
reactions with MDBP, maroon writing and side chains are for the dual S262C & S356C mutant. 
(b) LC-MS post reaction confirming Dha formation at position 199. (c) LC-MS post reaction 
confirming Dha formation at position 262. (d) LC-MS post reaction confirming Dha formation 
at position 356. (e) LC-MS post reaction confirming Dha formation at both 262 and 356 
positions in the duel mutant. (f) LC-MS post reaction confirming Dha formation at site 311.  
 
3.2.3. Single phosphorylation reactions at Dha  
 
 In order to install an accurate serine phosphorylation mimic at Dha, the protein must be 
reacted with sodium thiophosphate (Figure 3.5a). This reaction installs the phospho-amino 
acid phosphocysteine (pCys), which recapitulates all of the physiochemical properties of 
phosphorylation except for the P-S-C connection versus P-O-C. Before the reaction begins, the 
sodium thiophosphate needs to be prepared by mixing in an appropriate amount of HCl in order 
to bring the pH to approximately 8 (see Materials and Methods). Once this was complete, the 
sodium thiophosphate solution was slowly added to 100 µLs of Dha bearing tau (S199Dha, 
S262Dha, and S356Dha) in reaction buffer at 50 µM and allowed to react at 37 oC and 500 
rpm. After 4 hours the reaction was checked by LC-MS and revealed that it had only progressed 
to approximately 75% completion uniformly at the three positions (Figure 3.5b). Extending 


















Figure 3.5. pCys installation at single sites. (a) Reaction scheme for pCys installation on 
single Dha bearing tau mutants. (b) LC-MS spectrum of S199Dha reaction with sodium 
thiophosphate at 4 hrs, representative of the progress of the reaction at the other positions. (c) 
LC-MS spectrum of S199pCys after 8 hrs. (d) LC-MS spectrum of S262pCys after 8 hrs. (e) 




3.2.4. Attempted dual phosphorylation reactions at S262Dha & S356Dha mutant   
 
 Pursuing dual modifications via Dha is most commonly done on smaller peptides179, 
however it has been achieved on full proteins as well. Davis and co-workers were able to install 
two acetyl lysine mimetics on histone H3 using Dha as an intermediate160. While tau would be 
the largest protein dual modification has been attempted on by far, their succuss gave us hope 
that tau could be amenable to such an approach. With the S262Dha & S356Dha mutant in hand 
we initially attempted the dual pCys instalment using the same conditions as the single pCys 
reactions (Figure 3.6a). Checking the reaction after 6 hrs by LC-MS revealed that it had 
progressed to a near 50/50 mixture of single and dual pCys installation (Figure 3.6b). We 
extended the reaction initially out to 10 hrs and observed that there was about a 75% conversion 
to the desired dual modification (Figure 3.6c). Unfortunately, under these conditions this 
appeared to be the maximum conversion that we could observe. Extending the reaction out to 
24 hrs did not improve conversion of the singly modified population to dual modification and 
appeared to create some unwanted side products with unexpected mass shifts (Figure 3.6d). 
This was a consistent observation for many attempts to extend the reaction time. We attempted 
to increase the rate of the reaction by elevating the temperature to 45 oC (Figure 3.6a). To our 
dismay, checking by LC-MS after 6 hrs did not reveal an enhanced conversion to the desired 
dual modification (Figure 3.6e); on top of that more unexpected mass shifts of undesired side-
products were also observed.  
 A potential explanation for the inability to fully convert tau (S262Dha & S356Dha) to 
a dual pCys species is that, for a sub-population of the protein, a reactive lysine somewhere in 
the sequence has performed an intramolecular attack at one of the Dha’s. This would be 
undetectable by LC-MS as the mass of the protein would not change. One solution for this 
would be to drop the pH of the reaction (down to perhaps ~6) as then nearly all of the lysines 
on the protein will be protonated and thus incapable of a nucleophilic attack. However, this 
would also greatly reduce the rate of both the Dha conversions on the protein as well as the 
subsequent modification by sodium thiosulphate. Unfortunately, due to time constraints and 
the COVID-19 pandemic limiting lab capacity, we were unable to attempt a reaction using 










Tau (S262Dha & S356Dha) - pCys conversion at 6 hrs
Dual pCys addition 
Calc mass: 45874 Da
Obs mass: 45880 Da
Single pCys addition 
Calc mass: 45763 Da






Tau (S262Dha & S356Dha) - pCys conversion at 10 hrs
Dual pCys addition 
Calc mass: 45874 Da
Obs mass: 45881 Da
Single pCys addition 
Calc mass: 45763 Da
Obs mass: 45765 Da
Tau (S262Dha & S356Dha) - pCys conversion at 24 hrs
Dual pCys addition 
Calc mass: 45874 Da
Obs mass: 45877 Da
Single pCys addition 
Calc mass: 45763 Da




Figure 3.6. Attempted pCys installation on Tau (S262Dha & S356Dha). (a) Reaction 
schemes for both conditions pursued for this modification. (b) LC-MS of the reaction at 37 oC 
at 6 hrs. (c) LC-MS of the reaction at 37 oC at 10 hrs. (d) LC-MS of the reaction at 37 oC at 24 
hrs (representative of several attempts). (e) LC-MS of the reaction at 45 oC at 6 hrs. 
 
 
3.2.5. Acetylation and dimethylation mimic installations at K311Dha  
 
 While we were pleased with the amenability of Dha bearing tau to single pCys 
installation, we ideally wanted to prove that chemical mutagenesis can install a diverse array 
of less commonly studies PTMs on tau. Therefore, we pursued the installation of N-
acetylcysteamine and captamine at K311Dha. Reaction conditions were the same as previously 
used for sodium thiophosphate addition (20 mM NaPi [pH 8], 500 rpm) (Figure 3.7a). Taking 
a similar approach to the reactions with the antibodies in chapter 2 we kept the molar excess 
of these reagents to 1000 equivalents. Allowing the reactions to react overnight afforded the 







Tau (S262Dha & S356Dha) - pCys conversion at 45 oC and 6 hrs
Dual pCys addition 
Calc mass: 45874 Da
Obs mass: 45879 Da
Single pCys addition 
Calc mass: 45763 Da









Figure 3.7. PTM mimetic installation at K311Dha. (a) Reaction scheme for reacting tau 
(K311Dha) with captamine and N-acetlycysteamine. (b) LC-MS confirming homogenous 
addition of N-acetlycysteamine. (c) LC-MS confirming homogenous addition of captamine.  
 
 
3.2.6. Initial functional characterisation of tau chemical mutants 
 
 With the site-specific PTMs in hand, we sought to prove their ability to recapitulate 
known physiological consequences and then to characterise new PTMs in a tubulin 
polymerisation assay. Before any assays were conducted, the chemical mutants were first 
inspected by CD to verify no significant structural changes had occurred during the reaction 
process. Nearly all profiles were in perfect agreement with profile of unmodified tau, the profile 
for the K311Captamine mutant varied slightly but still had a profile very much matching a 




Figure 3.8. Tau chemical mutant CD spectra. CD spectrums of unmodified tau compared to 
the chemical mutant PTMs.  
 
 With the structures largely matching those of unmodified tau, the tubulin 
polymerisation assay could be pursued. To solutions of 3 mg/mL tubulin in assay buffer (80 
mM PIPES [pH 6.9], 2 mM MgCl2, and 0.5 mM EGTA) Tau was added to a final concentration 
of 15 µM, then the reaction was supplemented with GTP to a final concentration of 1 mM to 
initiate the polymerisation reaction immediately before inserting the plate and monitoring 
absorbance at 340 nm. This polymerisation assay is provided by Cytoskeleton Inc. and is a 
standard in the field of microtubule polymerisation, from studying tau’s role to screening small 
molecule inhibitors of polymerisation. It is also the same kit used by Lashuel and co-workers 
for all their characterisation of their semi-synthetic tau variants173,175. Screening the K311N-
acetylcysteamine variant first and directly comparing to the data from Ref [173] for the semi-
synthetic acetylated K280 revealed that our method exactly recapitulated the activity of this 
more arduously created construct (Figure 3.9a,b). 
 









































Figure 3.9. Comparison of polymerisation activity of acetylated K311 derived from 
chemical mutagenesis and acetylated K280 derived from semi-synthesis reveals similar 
profiles. (a) Tubulin polymerisation profiles of Tau and K311N-acetylcysteamine from this 
study. (b) Polymerisation data for semi-synthesised acetyl-K280 Tau from Ref [173] (adapted 
with permission).  
 
 The semi-synthesis approach has not yet been used to create full length phosphorylated 
tau at positions 262 and 356. Lashuel and co-workers have only applied this approach to install 
phosphates at these sites on the K18 fragment (just the four repeated sequences in the MBD) 
of tau175. As this fragment has a very different tubulin polymerisation profile compared to full 
length Tau, we sought to compare the polymerisation activity of our chemical mutants to in 
vitro phosphorylated tau by the kinase MARK1 that nearly exclusively phosphorylates at S262 
and S356 (although to differing extents, and with some phosphorylation at T212 and S214)171 
(Figure 3.10a). Our polymerisation reactions with S262pCys and S356pCys revealed that, as 
expected, both significantly inhibit the rate of tubulin polymerisation, with S356pCys having 
the greatest inhibitory effect (Figure 3.10b). The inhibitory activity we observe is in line with 
the large decrease in activity observed when tau is phosphorylated in vitro with MARK1 (note 
that the polymerisation conditions in Ref [171] were slightly different, hence the altered time 
scale). While studies using the phosphomimetic mutations of S262E and S356E are consistent 
in some regards to our results, such as how the S356E mutation almost completely inhibits 
polymerisation activity, the activity of S262E displays almost a linear polymerisation 
behaviour, rather than the delayed but no less sigmoidal profile of our chemical mutant180. This 
discrepancy may serve to highlight the subtleties in activity that are not capable of being 
recapitulated by cruder mimics.  
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Figure 3.10. Comparison of polymerisation activity of pCys tau mutants at position S262 
and S356 to naturally in vitro phosphorylated Tau by the MARK1 kinase. (a) Tubulin 
polymerisation activity and western blots revealing phosphorylation pattern for tau incubated 
with the kinase MARK1 (adapted with permission from Ref [171]). (b) Tubulin polymerisation 
activity of the pCys chemical mutants at site 262 and 356 created in this report.   
 
  
Serendipitously, another member of our group, Dr. Faidon Brotzakis, conducted 
molecular dynamics simulations of tau in complex with MTs with the aim to predict PTM sites 
that may regulate MT association. The approach used cryo-EM measurements to determine an 
ensemble of structures representing the structure and dynamics of a tau-microtubule complex 
comprising an extended microtubule-binding region of tau (residues 202-395). To predict tau 
residues that could be important for regulating MT stability, both the average number of 
contacts through the simulation and the root mean square fluctuations (RMSF) of the residues 
were quantified. If a residue has a high number of contacts (>7.5) it is likely to be a stabilising 
interaction and if its RMSF is significant it is also likely accessible for modifications by kinases 
or acetyltransferases. This analysis rightly predicted the know regulatory phosphorylation sites 
explored in this report of S262 and S356 (Figure 3.11a-c). Strikingly, it also predicted that 
acetylation at K311 was likely to have a very similar effect as acetylation at K280 that was 
verified through the results in this report (Figure 3.11d,e). Marrying this computational 
approach with the relatively rapid experimental verification by chemical mutagenesis could be 
a powerful approach for predicting PTMs regulating protein complex stability when cryo-EM 
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Figure 3.11. Molecular dynamics-based predictions of regulating PTM sites in tau’s 
MBD. (a) RMSF and average contact values of serine residues through the molecular dynamics 
simulation. (b) Ensemble interactions of S262 of tau with E434 of tubulin. (c) Ensemble 
interactions of S356 of tau with E434 of tubulin. (d) RMSF and average contact values of lysine 
residues through the molecular dynamics simulation. (e) Ensemble interactions of K311 of tau 
with R402 and E436 of tubulin. All figures provided by Dr. Faidon Brotzakis.  
 
 
With the accuracy of the acetylation and phosphorylation chemical mutant mimetics 
established, we sought to characterise the polymerisation activity of our poorly understood 
mimics of K311 dimethylation and S199 phosphorylation. The dimethylation mimic 
(K311Captamine) showed a very small and likely insignificant delay in tau’s polymerisation 
activity (Figure 3.11a). Meanwhile, the S199pCys mutant inhibited tubulin polymerisation to 
a nearly identical extent as the S262pCys chemical mutant (Figure 3.11b). At first glance, this 
is a very surprising result since S199 is well within the PRD of tau, compared to the very central 
position of S262 in the MBD. However, several studies in the literature can serve to lend 
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credence to this result. An early study of the regions of Tau demonstrated that when the PRD 
is deleted tau is incapable of polymerising tubulin181. A more recent study has found that the 
PRD alone is capable of binding tubulin tightly and stoichiometrically and is capable of 
initiating polymerisation, and to an even greater extent that the MBD alone182. This study goes 
much further in its characterisation of this domain and shows that the PRD is actually likely 
the core tubulin binding domain of tau that begins the polymerisation process that is then 
further enhanced by the MBD, with the entire process being negatively regulated through 
intramolecular interactions with the N-terminal domain (Figure 3.11c). With phosphorylation 
at S199 a known biomarker for AD progression176,177, it is possible that this association stems 
from this modification interfering with the initiation of tubulin polymerisation by the PRD in 
the model proposed in Ref [182] (Figure 3.11c), and thus leading to higher levels of unbound 























Figure 3.12. Tubulin polymerisation by K311Captamine and S199pCys and 
polymerisation model. (a) Tubulin polymerisation of Tau (K311Captamine) compared to Tau 
and Tau (K311N-acetylcysteamine). (b) Tubulin polymerisation of Tau (S199pCys) compared 
to Tau and Tau (S262pCys), showing near perfect overlap of in activity of S199pCys and 
S262pCys. (c) Initiation of tubulin polymerisation model described in Ref [182] and the 
potential step that phosphorylation at S199 could disrupt.  
 
 


















































3.3 Conclusions  
  
 The aim of this chapter was to explore the amenability of Tau for chemical mutagenesis 
to enable relatively easy access to highly accurate PTMs to facilitate their study. To this end, 
we pursued the installation of a pCys phosphorylation mimetic via Dha at three different sites, 
one variant with two pCys modification sites, and two lysine PTM mimetics, acetylation and 
demethylation, at one site. At the outset, we determined that the commonly used reagent 
DBHDA for converting cysteine to Dha formed a stable intermediate on the protein and could 
not be used. However, we found that a recently developed more reactive molecule for this 
purpose, MDBP, effectively installed Dha at a reasonable timescale for all sites investigated in 
this report. The subsequent additions of the PTM mimetics went smoothly for all of the tau 
variants containing single Dha residues. Dual modification at the S262Dha & S356Dha double 
mutant proved to be difficult to reach homogenous conversion to the dual pCys mutation, 
possibly due to an intramolecular attack by a reactive lysine. Unfortunately, due to time-
constraints and the limited work capacity in the lab during the COVID-19 pandemic this could 
not be optimise further.  
 With the successful production of the single chemical mutants we performed an initial 
characterisation of their effects on tau’s important physiological function of tubulin 
polymerisation. The data from the polymerisation of our K311 acetylation mimic greatly 
supported the physiological validity of our chemical mutants as it perfectly replicated the 
polymerisation profile of acetylated K280 (located within a similar motif) generated through a 
laborious semi-synthesis protocol. This was then further corroborated with the polymerisation 
data for S262pCys and S356pCys, which both showed a significant inhibition of activity in line 
with data from in vitro phosphorylated tau by the kinase MARK1 that phosphorylates primarily 
at these sites. Validating the accuracy of these chemically installed PTMs was a very important 
goal of this project, as we can now have a faith in the results from newly explored PTMs. Of 
the two new PTMs investigated in this early characterisation, we observed an initially 
unexpected significant inhibition of polymerisation by the installation of pCys at S199 in the 
PRD. However, looking at both distant and recent literature on the PRD and its role in tau 
function provides a rational explanation as the PRD has an increasingly supported role in the 
initiation and elongation steps of tubulin polymerisation that has largely been 
underappreciated182. While more work will need to be carried out to fully validate this 
hypothesis, from our data it appears that phosphorylation at S199 may play a role in regulating 
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the capability of the PRD to associate with tubulin and may form a basis for explaining this 
modification’s pathological association. This tantalizing result serves to highlight the potential 
for chemical mutagenesis to facilitate the study of tau PTMs and their undoubtably numerous 
functional consequences. We hope that this brief and primarily methodological report will 
enable the field with a relatively facile method, and we look forward to further results on the 





































Chapter 4: Discussion and future work   
 
4.1 Chapter 2 discussion and future work 
 
Since the beginning of the research reported in chapter 2, a plethora of studies have 
been published with the aim of augmenting protein activity using non-canonical amino acids. 
New catalytic mechanisms, previously impossible for natural enzymes, have been enabled 
through the incorporation of non-canonical residues in active sites183,184. While these studies 
relied on genetic code-expansion technology, they still highlight the growing use case for 
expanding side-chain diversity. In the context of protein-protein recognition, Rogers and co-
workers provided a seminal study validating the utility of non-canonical amino acids in 
augmenting binding interactions185. Using an in vitro translation system with flexizymes 
(flexible tRNA-acylation ribozymes that can load many non-canonical amino acids) the 
researchers were able to incorporate 21 non-canonical amino acids throughout the 27-amino 
acid sequence of the BH3 domain of the protein PUMA. The binding of this domain to its 
partner, the protein MCL1, has been a model system for studying protein-protein 
interactions186. Using this approach, they were able to find and combine 5 potentiating 
mutations that increased the affinity 25-fold over the natural sequence (from an already potent 
KD of 4 nM to 160 pM). In line with our findings, many of the single substitutions with non-
canonical side chains led to a nearly complete loss of activity in this system. They also observed 
that changes as small as single methyl groups led to drastic changes in binding energies. 
Together with our results, it appears that the “magic methyl” effect long seen in small molecule 
drug design may extend to the case of non-canonical amino acids in protein-protein 
interactions187.  
Along with these studies supporting the general use of non-canonical sidechains, the 
chemistry available for chemical mutagenesis has also been advanced since the beginning of 
the work in this report, both for the installation and modification of Dha. Yang and co-workers 
developed a proximity enabled intramolecular reaction to install Dha or its close analogue 
dehydrobutyrine (Dhb, addition of a single methyl group)188. The installation relies on the 
incorporation of the UAA fluorosulfate-L-tyrosine through genetic code expansion proximally 
to a Ser or Thr residue where Dha/Dhb is ultimately desired; at the end of the reaction the 
fluorosulfate-L-tyrosine is converted to normal tyrosine. This system allows for the 
incorporation of Dha/Dhb into proteins that may not be amenable to extended reaction 
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conditions with traditional reagents and can even install Dha/Dhb in living systems. Along with 
this, a new and improved reaction for the installation of C(sp3)-C(sp3) bonds at Dha has also 
been recently reported189. The Davis lab again leads the way in this innovation. Instead of using 
halogen bearing chemical mutant precursors, this new approach relies on boronic acid catechol 
ester precursors that can generate RH2C• radicals when illuminated with blue light (450 nm) 
in the presence of a widely available ruthenium catalyst in a range of pH’s and temperatures. 
These chemical advances should further the amenability of different substrates to chemical 
mutagenesis mediated side-chain diversification.  
 Our results for using chemical mutagenesis to systematically enhance antibody 
activity will hopefully motivate more research into this application of chemical mutagenesis. 
Due to the nature of the target of the starting antibody in this study, we had to take an empirical 
approach initially and screen a large variety of sidechains. In the future, an interesting 
application would be to use SAR via chemical mutagenesis to rationally improve the activity 
of an antibody using structural information of it bound to the antigen. Iterative rounds of side-
chain diversification followed by activity screening and structural characterisation can then 
truly follow the traditional workflow taken by medicinal chemists. This may prove to be an 
appropriate route to activity maturation for starting candidates targeting highly conserved 
clinically relevant epitopes, such as those of viral surface proteins. Especially when the 
potential development of escape mutations in most protein regions is very high190. Another 
very recent and exciting development in protein-based therapeutics that could be amenable to 
this chemical mutagenesis approach is that of proximity enabled reactive therapeutics 
(PERx)191. The Wang group at UCSF has just developed the first example of such a therapeutic.  
This molecule interferes in the programmed cell death protein-1 (PD-1) signalling pathway, 
which is a key mediator of suppressing the immune response in cancers and many other 
diseases192.  In their approach, a latently reactive UAA was installed at a critical site within 
recombinant programmed cell death protein-1 (PD-1). This then covalently reacts upon binding 
to its ligand (PD-L1) on the surface of cancer cells and prevents them from evading destruction 
by capping this signalling domain with the inert PD-1. Chemical mutagenesis on antibodies 
could prove to be an excellent means to develop similar therapeutics for a variety of targets. 
The ability to install a wide variety of potential PERx appropriate sidechains at many sites 
through a post-expression protocol would greatly accelerate the optimisation process, rather 
than expressing/purifying many variants with UAAs introduced through genetic codon 
expansion technology. A potential use case for applying PERx with antibodies in AD would 
be for an antibody that specifically targets the secondary nucleation sites along the fibril 
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surface. When such an antibody is developed, if it is merged with PERx through chemical 
mutagenesis, it would in effect nullify the production of toxic oligomers permanently. As 
evident through these developments in the field during the work carried out in this thesis, the 
application of advanced chemical biology tools in biotechnology is happening at an ever-
increasing pace. We anticipate that the application of chemical mutagenesis for antibody 
development will exceed that of SAR studies alone in the future.  
 
4.2 Chapter 3 discussion and future work 
 
 Large advances in the use of chemical mutagenesis to study of ever more complex 
PTMs has also occurred since the beginning of the work on Tau reported in this thesis. Perhaps 
the most striking example of this has been the elucidation of the multiphase reaction 
mechanism of glycogenin in initiation of glycogenesis174.  This study did not utilise Dha, but 
instead a very clever incorporation of another synthetically versatile non-canonical amino acid 
p-iodophenylalanine in place of a catalytic tyrosine residue (Tyr195). In the cell, this tyrosine 
acts as the initiator site of the polymerisation of glycogen through a stepwise autocatalytic 
process. By replacing this residue with p-iodophenylalanine, the researchers were able to 
precisely probe activity by conjugating boronic acid bearing oligosaccharides of specific 
lengths and compositions to this site through a palladium mediated Suzuki-Miyaura cross 
coupling reaction. Through the installation of these precise intermediates, the researchers 
revealed a triphasic kinetic mechanism for the autoglucosylation reaction and a “proof-
reading” mechanism of the enzyme to ensure the fidelity of the growing polysaccharide. This 
study is an elegant example of using a different reaction available to chemical biologists to 
study increasingly complex PTM mediated protein behaviour.  
 The significance of diverse tau PTMs on its pathogenesis has only become more 
apparent since the beginning of this work. The Fitzpatrick lab recently made the first definitive 
observation of PTMs influencing the formation of strain-specific structures in individual 
tauopathies193. Using patient derived amyloid fibrils from AD and corticobasal degeneration 
(CBD), the team combined cryo-EM structural determination with mass-spectrometry to map 
PTM sites and their influence on the distinct fibril morphologies in these two tauopathies. This 
comprehensive biophysical characterisation revealed that CBD fibrils are heavily post-
translationally modified compared to AD derived fibrils, and that specific sites with consistent 
ubiquitination in CBD were key mediators of inter-protofilament interfaces, heavily 
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influencing the morphology of the fibrils. Their analysis also elucidated that acetylation at 
K311 was a key modification in AD fibrils that determined the favourability of forming paired 
helical filaments over straight filaments. More generally, they also observed that lysine 
acetylation likely creates favourable conditions for b-strand stacking within the fibrils.  
 Sadly, the plans for our studies of tau PTMs was cut short because of restrictions put in 
place due to the ongoing pandemic. However, the preliminary data presented here on the 
amenability of tau to chemical mutagenesis and the physiological accuracy of the PTM 
mimetics is very encouraging for the application of this technique to study tau modifications. 
One of the most intriguing results was the effect of phosphorylation at Ser 199 on tubulin 
polymerisation. Future work is needed to definitively establish if this modification is truly 
involved in the regulation of the PRD’s role in tubulin association. This could be probed by 
purifying tau truncated to solely the PRD and accurately quantifying the effects of the 
S199pCys modification on tubulin binding. An initial characterisation could be carried out 
using BLI in order to get detailed kinetic data on the PTM’s effect. Elucidating all the 
mechanisms behind S199 phosphorylation’s pathological association will also likely need 
some characterisation of its effect on tau’s fibrillization. Unfortunately, a physiologically 
relevant in vitro aggregation assay has not yet been developed for full-length tau, and 
aggregation studies using fragments almost exclusively focus on variations of the MBD and C-
terminal region. Therefore, to fully explore the potential effects of this modification, 
aggregation screens would likely need to be conducted with a series of truncated tau variants 
containing the PRD and varying regions of the MDB and C-terminus.  
 To more comprehensively study PTMs on tau and their potential ability to “cross-talk,” 
the dual modification reaction will also need to be optimised in the future. The working 
hypothesis of an intramolecular attack by a reactive lysine as the reason behind the inability of 
the S262Dha & S356Dha to react to completion with sodium thiophosphate could be assessed 
by LC-MS/MS. If this is indeed what is occurring, then the pH of the reaction will need to be 
dropped in order to nullify the lysine residues. This could also be an issue that is unique to 
these positions if this is the case. Once this hurdle is overcome, studying the cumulative effects 
of PTMs on tau behaviour will be more readily accessible than the established semi-synthesis 
method. When these protocols for chemical mutagenesis on tau are published, we hope this 
will provide a widely accessible method for the field to accurately study the effects of PTMs 
on this crucial protein.   
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4.3 Potential of chemical mutagenesis  
 
The overarching aim of the work described in this thesis was to explore a new 
application of chemical mutagenesis and to apply established techniques within the field to a 
new and important protein, all within the context of Alzheimer’s disease. These goals fit into 
the greater context within chemical biology of widening the utility and use cases of chemical 
tools. While nature is largely limited to synthesising proteins with the 20 canonical amino 
acids, life greatly expands the functions and behaviour of proteins through the myriad of 
cellular systems responsible for PTMs. Chemically simple PTMs, such as methylation, to 
more complex modifications, such as glycosylation, have profound influences on biological 
processes in all kingdoms of life. To enable true synthetic biology, life scientists will need 
powerful techniques to rationally expand the chemical space of proteins. Due to the inherent 
limitations of the protein biosynthesis machinery, approaches beyond gene-codon expansion 
technology must be embraced to accomplish this. Ideally, these methods will not be overly 
complex and could be rapidly adopted by the field as a whole, similar to how site-directed 
mutagenesis is implemented in labs across the world today. This will enable the development 
of synthetic biology in the coming century to match the advances seen in synthetic chemistry 
during the previous century.  The applications explored in the research presented here of 
enabling a SAR study to augment protein function and to investigate disease relevant PTMs 
have wide applicability to many areas of biology and biotechnology. With the accelerating 
pace that chemical mutagenesis is being readopted and improved, there are likely many more 
applications to come that we cannot yet envisage. This is a truly exciting time to be at the 










Chapter 5: Materials and methods 
 
5.1 DesAB-Aß 3-9 and its mutants’ expression and purification  
 
All antibodies were expressed with an N-terminal hexa-histidine tag from a pRSET-B 
vector in E. coli BL21 (DE3)-Gold strain (Agilent Technologies). Cultures were grown in 
modified Terrific Broth media (Sigma-Aldrich) supplemented with ampicillin (100 µg/ml) at 
37 ºC and induced with 1 mM isopropyl β- d-1-thiogalactopyranoside (IPTG) at an optical 
density (OD) of approximately 0.8 and were then left to express overnight at 28 ºC. Cells were 
harvested by centrifugation and re-suspended in standard phosphate buffered saline (PBS) with 
the addition of one EDTA-Free Complete Protease Inhibitor Cocktail Tablet (Roche) per 500 
mL of cell culture and subsequently lysed by sonication (5 min total, 15 s on and 45 s off, 40% 
amp, on ice). Cellular debris was removed by centrifugation at 15,000 rpm (JA-20 rotor, 
Beckman Coulter). The cleared lysate was then loaded onto loose Ni2+-NTA resin (Thermo 
Fisher) previously equilibrated with PBS containing 10 mM imidazole. After washing the 
loaded resin with PBS containing 40 mM imidazole the protein was eluted with buffer 
containing 200 mM imidazole. The excess imidazole was subsequently removed during size-
exclusion chromatography (SEC) using a HiLoad 16/600 Superdex 75 pg column (GE 
Healthcare LifeSciences, Little Chalfont, U.K.) into PBS, previous to the SEC the protein was 
incubated with 1 mM dithiothreitol (DTT) for 30 minutes to reduce any dimers that may have 
formed. The sequence of the singe-domain antibody used is as follows, with the designed 







5.2 Tau expression and purification  
  
 Tau and its cysteine mutants used in this study were expressed from BL21 Gold DE3 
cells (Agilent). Batches of 6 x 1 L cultures of LB medium with 100 µg/mL ampicillin were 
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inoculated with 5 mL of overnight culture and grown at 37 oC until an OD 600 nm reached 0.6. 
Expression was then induced with the addition of IPTG to a final concentration of 0.4 mM, 
whereupon the temperature was reduced to 18 oC and the cultures were allowed to express 
overnight. Cells were harvested in the morning by centrifugation at 6000 g for 30 min at 4 oC. 
Pelleted cells were resuspended in lysis buffer (50 mM MES [pH 6.5], 5 mM DTT, 0.1 mM 
PMSF) and lysed on ice via sonication (1.5 min total, 5 s on/10 s off, 40% amplitude). Lysate 
was cleared via centrifugation at 18000g for 30 min at 4oC. To the supernatant DNAse and 
RNAse was added (0.1 mg/mL) and allowed to sit at room temperature for 5 minutes. 
Supernatant was then passed through a 0.45 µm syringe filter to remove any particulates. 
Cation exchange chromatography was then performed using a Hitrap CaptoS column (GE 
Healthcare) equilibrated with 5 CV ddH2O, then 5 CV lysis buffer + 1 M NaCl, then 5 CV lysis 
buffer. The lysate was then loaded at 5 mL/min and washed with 10 CV of lysis buffer. The 
protein was eluted at a rate of 5 mL/min with 5 mL fractions being collected through a 0-500 
mM gradient of NaCl over 10 CV. Fractions were assessed via SDS-PAGE for the presence of 
Tau and all appropriate fractions were pooled and precipitated with ammonium sulphate (20% 
w/v) and left overnight on ice. Precipitated proteins were pelleted at 16000 g for 30 min at 4 
oC and then resuspended in 1 x SSPE buffer with 5 mM DTT. Size exclusion chromatography 
was then performed using a Superdex 200 Increase 10/300 GL column (GE Healthcare) 
equilibrated in the same resuspension buffer. Proteins were injected and ran at a flow rate of 
0.75 mL/min. Fractions corresponding to the appropriate UV signal were pooled and assessed 
by SDS-PAGE for purity, only the purest fractions of Tau were kept for experiments and the 
rest was pooled and frozen for subsequent SECs to isolate more pure Tau when needed.  
 
5.3 Site-directed mutagenesis  
 
 All site-directed mutagenesis carried out in this thesis was done using the methods 
described in Ref [169]. Mutagenic primers were designed with overlapping sequences at the 5’ 
end and non-overlapping portions at the 3’ end of the sequence. This allows for the primers to 
use their PCR products as templates as the non-overlapping regions can bridge the “nicks” in 
DNA of newly synthesised products. Non-overlapping regions were designed to have a Tm 5 
to 10 oC higher than the overlapping regions of the primers, which contained the desired 
mutations. All primers were ordered from Sigma Aldrich. PCR reactions were conducted in a 
total volume or 50 µL with reagents supplied from New England Biolabs (NEB) (10 µL 5x 
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reaction buffer, 250 µM dNTPs, 1 µg/mL each primer, 20 ng starting template, 2 µL DMSO, 
0.5 µL Phusion HF polymerase). The thermocycler conditions were as follows: 30 s initial 
denaturation (98 oC), 10 s denaturation (98 oC), 30 s annealing at Tm overlap -5 oC, 5 minutes 
elongation (72 oC) with the previous 3 steps repeated for 30 cycles, a last annealing step was 
performed for 30 s at Tm overlap -5 oC and then the last extension was for 7 minutes. PCR 
reactions were then treated with fast digest DPN1 (1 µL, NEB) at 37 oC for 4 hrs to digest any 
starting template. Samples were then cleaned using a Qiagen PCR clean kit before being 
transformed into XL-10 Blue ultracompetent cells (Agilent). Colonies from the transformations 
had the plasmids harvested for sequencing using a Qiagen miniprep kit after growing in 5 mL 
LB cultures overnight. All primers used in this report can be seen below:  
H136C-  
Fwd: 5’- GGATCTTGCGAAACCCTGACCCTGCGCGAGGA-3’  
Rev: 5’- GGTTTCGCAAGATCCCGCTGCGCAATAATACACAGC-3’  
Tm Overlap: 50.6 C                             
Tm Non-overlap: 59.8 C Fwd, 58.4 C Rev      
E137C-  
Fwd: 5’- ATCTCATTGCACCCTGACCCTGCGCGAGGAAGA-3’ 
Rev: 5’- TCAGGGTGCAATGAGATCCCGCTGCGCAATAATAC-3’  
Tm Overlap: 49.9 C  
Tm Non-overlap: 55.9 C Fwd, 56.3 C Rev 
T138C-  
Fwd: 5’-CATGAATGCCTGACCCTGCGCGAGGAAGAGGCG-3’  
Rev: 5’-GGGTCAGGCATTCATGAGATCCCGCTGCGCAATAATA-3’  
Tm Overlap: 50.6 C  
Tm Non-overlap: 59.8 C Fwd, 59.5 C Rev 
L139C-  
Fwd: 5’- TGAAACCTGCACCCTGCGCGAGGAAGAGGCGG-3’ 
Rev: 5’-CAGGGTGCAGGTTTCATGAGATCCCGCTGCGCAA-3’  
Tm Overlap: 50.6 C  
Tm Non-overlap: 58.4 C Fwd, 58.4 C Rev 
T140C- 
Fwd: 5’-ACCCTGTGCCTGCGCGAGGAAGAGGCGGCC-3’  
Rev: 5’-CGCAGGCACAGGGTTTCATGAGATCCCGCTGCG-5’ 
Tm Overlap: 49.4 C 
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Tm Non-overlap: 58.4C Fwd, 59.5C Rev     
L141C- 
Fwd: 5’-CTGACCTGCCGCGAGGAAGAGGCGGCCGC-3’  
Rev: 5’-TCGCGGCAGGTCAGGGTTTCATGAGATCCCGCT-3’ 
Tm Overlap: 49.4 C  
Tm Non-overlap: 57 C Fwd, 57.5 C Rev     
R142C- 
Fwd: 5’-ACCCTGTGCGAGGAAGAGGCGGCCGCGTG-3’  
Rev: 5’-TTCCTCGCACAGGGTCAGGGTTTCATGAGATCCC-3’  
Tm Overlap: 48.8 C  
Tm Non-overlap: 55.6 C Fwd, 56.3 C Rev           
T138K- 
Rev: 5’-GGGTCAGCTTTTCATGAGATCCCGCTGCGCAATAATA-3’ 
Fwd: 5’- CATGAAAAGCTGACCCTGCGCGAGGAAGAGGCG-3’ 
Tm Overlap= 48.2 C 




Tm Overlap = 52.4 C 
Tm Non-overlap = 60.5 C Fwd, 58.4 C Rev 
Tau S262C- 
Fwd: 5’- CGGTTGTACCGAAAACCTGAAACACCAGCCGGGTGG-3’ 
Rev: 5’- GGTTTTCGGTACAACCGATTTTAGATTTAACGTTTTTCAGGTCC-3’ 
Tm Overlap = 52.4 C  
Tm Non-overlap = 61.6 C Fwd, 60.8 C Rev 
Tau S356C- 
Fwd: 5’- CGGTTGTCTGGACAACATCACCCACGTTCCGGGTG-3’ 
Rev: 5’- GTTGTCCAGACAACCGATTTTAGACTGAACACGGTCTTTG-3’ 
Tm Overlap = 52.4 C 





Tm Overlap = 56.3 C  
Tm Non-overlap Fwd = 63.7 C Fwd, 63.2 C Rev 
 
5.4 Protein liquid chromatography - mass spectrometry (LC-MS) 
 
Protein LC–MS was performed on a Xevo G2-S TOF mass spectrometer coupled to an 
Acquity UPLC system using an Acquity UPLC BEH300 C4 column (1.7 μm, 2.1 mm × 50 
mm). Water with 0.1% formic acid (solvent A) and 95% MeCN and 5% water with 0.1% formic 
acid (solvent B) were used as the mobile phase at a flow rate of 0.2 mL/min. The gradient was 
programmed as follows: 95% A for 0.93 min, then a gradient to 100% B over 4.28 min, then 
100% B for 1.04 minutes, then a gradient to 95% A over 1.04 min. The electrospray source 
was operated with a capillary voltage of 2.0 kV and a cone voltage of 40 V. Nitrogen was used 
as the desolvation gas at a total flow of 850 L/h. Total mass spectra were reconstructed from 
the ion series using the MaxEnt algorithm preinstalled on MassLynx software (v4.1 from 
Waters) according to the manufacturer’s instructions. Representative total ion chromatographs 
(TICs) for the antibodies and Tau and the regions integrated for analysis are shown below 







Figure 5.1. Representative TICs for the antibodies and for Tau. (a) Representative TIC 
from DesAB-Ab3-9(T138C). (b) Representative TIC of Tau from Tau(S356C). Black bars 
indicate the regions of the chromatograms containing the desired protein ions. 
 
 
5.5 Liquid chromatography with tandem mass spectrometry (LC-MS/MS)  
 
Protein solutions were reduced with DTT, alkylated with iodoacetamide, and subjected 
to enzymatic digestion with chymotrypsin at 37 °C. After digestion, the peptide solutions were 
pipetted into sample vials and loaded onto an autosampler for automated LC-MS/MS analysis. 
All LC-MS/MS experiments were performed using a Dionex Ultimate 3000 RSLC nanoUPLC 
(Thermo Fisher Scientific Inc, Waltham, MA, USA) system and a QExactive Orbitrap mass 
spectrometer (Thermo Fisher Scientific Inc, Waltham, MA, USA). The separation of peptides 
was performed by reverse-phase chromatography at a flow rate of 300 nL/min and a Thermo 
Scientific reverse-phase nano Easy-spray column (Thermo Scientific PepMap C18, 2 µm 
particle size, 100 Å pore size, 75 µm inside diameter (i.d.) x 50 cm length). Peptides were 
loaded onto a pre-column (Thermo Scientific PepMap 100 C18, 5 µm particle size, 100 Å pore 
size, 300 µm i.d. x 5 mm length) from the Ultimate 3000 autosampler with 0.1% formic acid 
for 3 minutes at a flow rate of 10 µL/min. After this period, the column valve was switched to 
allow elution of peptides from the pre-column onto the analytical column. Solvent A was water 
+ 0.1% formic acid and solvent B was 80% acetonitrile, 20% water + 0.1% formic acid. The 
linear gradient employed was 2-40% B in 30 minutes. The LC eluant was sprayed into the mass 
spectrometer by means of an Easy-Spray source (Thermo Fisher Scientific Inc.). All m/z values 
of eluting ions were measured in an Orbitrap mass analyzer, set at a resolution of 70,000 and 
was scanned between m/z 380-1500. Data dependent scans (top 20) were employed to 
automatically isolate and generate fragment ions by higher energy collisional dissociation 
(HCD) and 25% normalized collisional energy (NCE) in the HCD collision cell and 
measurement of the resulting fragment ions was performed in the Orbitrap analyzer, set at a 
resolution of 17,500.  Singly charged ions and ions with unassigned charge states were 
excluded from being selected for MS/MS and a dynamic exclusion window of 20 seconds was 
employed. All MS/MS data were converted to mgf files and the files were then submitted to 
the Mascot search algorithm (Matrix Science, London UK) and searched against a custom 
database containing the UniProt human database and four sequences relating the 4 proteins 
which were analyzed. Variable modifications of oxidation (M), deamidation (NQ) and beta 
 139 
mercaptoethanol and a fixed modification of carbamidomethyl were applied. The peptide and 
fragment mass tolerances were set to 20 ppm and 0.1 Da, respectively. A significance threshold 
value of p<0.05 and a peptide cut-off score of 20 were also applied. 
 
5.6 Synthesis of 2-mercaptoethyl-N,N,N-trimethylammonium chloride 
 
5 g of 2-(bromoethyl)-trimethylammonium bromide (1 eq, 4.88 mmol) was transferred 
into a 250 mL round bottom flask and dissolved in 25 mL H2O. 3 g of potassium thioacetate 
(1.3 eq, 26.3 mmol) was added to the previous solution and the mixture was heated to 60 °C 
and stirred overnight. The resulting mixture was concentrated under reduced pressure. The 
product was extracted by stirring the resulting solid in 100 mL of a solution of [1:1] 
MeOH/CH2Cl2 at room temperature for 15 min. This process was repeated twice in order to 
remove KBr. The mixture was filtered, and the filtrate was concentrated under reduced 
pressure. The expected product 2-(acetothioethyl)-trimethylammonium bromide was formed 
(4.88 g, 97%) and used without purification. 1H NMR (D2O, 400 MHz): d = 2.27 ppm (3H, s, 
Ac), 3.04 ppm (9H, s, NMe3), 3.13-3.17 ppm (2H, m, CH2), 3.32-3.37 ppm (2H, m, CH2). 
13C NMR (D2O, 100 MHz): d = 21.5, 29.8, 52.8, 64.3 ppm. 1.19 g of the previous product 
was transferred into a 100 mL round bottom flask and dissolved in 10 mL 6M HCl. The solution 
was heated to 85 °C and stirred for 1 h. The resulting solution was concentrated under reduced 
pressure and dried under vacuum. The product 2-mercatoethyl-N,N,N-trimethylammonium 
chloride was formed (1.12 g, 94%) and used without purification. 1H NMR (D2O, 400 MHz): 
d = 2.85-2.90 ppm (2H, m, CH2), 3.07 ppm (9H, s, NMe3), 3.12 ppm (1H, s, SH), 3.43-3.49 
ppm (2H, m, CH2). 13C NMR (D2O, 100 MHz): d = 16.6, 52.9, 67.8 ppm. 
 
5.7 Amyloid-ß aggregation assay  
 
Lyophilized Ab42 peptide was dissolved in 6 M guanidinium chloride (20 mM NaPi, 
200 µM EDTA, pH 8) and incubated for 3 h on ice. This solution was then buffer exchanged 
into buffer containing 20 mM NaPi and 200 µM EDTA at pH 8 by SEC using a Superdex 75 
10/300 GL column (GE Healthcare), and the peak belonging to monomeric Ab42 peptide was 
isolated and collected in protein low-binding Eppendorf tubes (Corning) on ice. Aggregation 
reactions were prepared by creating solutions of 1.5 µM Ab42 in the presence of DesAb 
derivatives in at ratios from 1:2 DesAb to Ab42  and decreasing down to 1:8, ThT was added 
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to a final concentration of 20 µM. Samples were loaded by pipette into 96-well half-area plates 
of black polystyrene with clear bottoms and polyethylene glycol coatings (Corning) (80 µL 
sample/well). Once all samples were loaded plates were sealed to prevent evaporation. 
Aggregation reactions were carried out at 37 ºC under quiescent conditions using a 
CLARIOstar plate reader (BMG Labtech). ThT fluorescence was measured every 2 min 
through the bottom of the plate with an excitation filter of 440 nm and an emissions filter of 
480 nm. To create Ab42 fibrils for the seeded assays, 5 µM Ab42 was incubated at 37 ºC under 
quiescent conditions overnight in protein low-binding Eppendorf tubes (Corning). The fibrils 
were vigorously pipetted up and down before being added to the aggregation reaction to a final 
concentration of 30% monomer-equivalents.  
 
5.8 Biolayer interferometry (BLI) 
  
A streptavidin biosensor (ForteBio, Menlo Park, USA) was coated with 5 µg/ml 
monomeric C-terminally biotinyl ated Ab42 (AnaSpec, Fremont, USA) in PBS + 0.1% BSA 
(w/v) + 0.02% TWEEN 20 by overnight incubation at 5 °C. Control sensors were coated with 
the same concentration of biocytin (Sigma). Tips were rinsed before binding experiments by 
incubation for 1 h at 30 ºC. The association of the antibodies was monitored at concentration 
of 20 µM in the buffer previously described for 900 s at 30 ºC using an Octet Red96 (ForteBio, 
Menlo Park, USA). The dissociation was monitored by subsequently placing the sensors into 
a well containing pure buffer for a further 1200 s. The binding of the antibodies to the biocytin 
coated streptavidin sensors was subtracted from the signals for immobilized Ab42 to account 
for non-specific binding. The binding data was analyzed using the Octet software as per the 
manufacturer’s instructions. 
 
5.9 Dha formation on the single-domain antibodies 
 
Cysteine mutants were pre-treated with 100x DTT while shaking at room temperature for 30 
minutes, excess DTT was subsequently removed and the protein was buffer exchanged into the 
reaction buffer (20 mM sodium phosphate buffer (NaPi) at pH 8) by a Zeba Spin desalting 
column equilibrated with the desired buffer. Protein at concentrations between 75-100 µM was 
added to 500x solid 2,5-dibromo-1,6-dihexamide (DBHDA, Enamine Ltd.) and left shaking at 
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37 ºC for 5 hours. The reaction was monitored by LC-MS and when full conversion to Dha 
was observed excess DBHDA was removed by centrifugation (5 min, 10,000g, 4 ºC).  
 
5.10 Dha formation on Tau 
 
The Tau cysteine mutants were buffer exchanged into 20 mM NaPi buffer (pH 8) via 7k 
MWCO Zeba spin desalting columns (Thermo Fisher). 200 µL of 50 µM protein aliquots were 
reacted with 50 molar equivalents of methyl 2,5-dibromopentanoate (Sigma Aldrich) per 
cysteine for 12 hours at 37 oC and shaking at 500 rpm. Excess methyl 2,5-dibromopentanoate 
was removed by passing the reactions through 7k MWCO Zeba spin desalting columns and 
then conversion to Dha was verified via LC-MS.  
 
5.11 Circular dichroism 
 
Circular dichroism (CD) spectroscopy was used to analyze protein secondary structure in 
solution. Antibody samples were diluted to 5 µM in PBS and CD measurements were recorded 
using a Chirascan spectrophotometer equipped with a Quantum TC125 temperature control 
unit (25 ºC). The data was acquired in a 0.1 cm path length with a response time of 1 s, a per-
point acquisition delay of 5 ms and a pre- and post-scan delay of 50 ms. Spectra were averaged 
over three scans, in a wavelength range from 200 nm to 250 nm, and the spectrum from a blank 
sample containing only buffer was subtracted from the averaged data. The structural stability 
of the proteins was analyzed by monitoring the CD signal at 207 nm from 20 to 98 °C at a rate 
of 0.5°C min−1. Data points were acquired every 0.1 °C with a bandwidth of 1 nm. Analysis of 
the thermal unfolding curves was performed, assuming a two-state unfolding model. Tau and 
its chemical mutants were diluted to 2 µM in 20 mM sodium phosphate buffer and scanned in 
the same manner except that the range was extended to 195 nm to 250 nm.  
 
5.12 Kinetic analysis  
 
All kinetic analysis was performed using a MatLab script provided from Ref [9]. The time 
evolution of the total fibril mass concentration, M(t), in the absence of seeds is defined by the 













where the parameters are described in detail in previous studies9,85. These are functions 
containing the combinations of the two microscopic rate constants k+kn and k+k2 where kn, k+, 
and k2 are the primary nucleation, elongation, and secondary nucleation rates respectively. The 
antibodies can perturb the aggregation reaction by inhibiting one or multiple steps. By applying 
the above equation to describe the macroscopic profiles we extract the k+kn and k+k2 parameters 
that best fit the data to enable accurate comparisons of inhibition mechanisms. 
 
5.13 Tubulin polymerisation assay 
 
The microtubule polymerisations were all performed with reagents from the kit 
purchased from Cytoskeleton, Inc. (Cat #BK006P) as per manufacturer’s instructions. Tubulin 
as added to the reaction mixture at a concentration of 3 mg/ mL and Tau and the various 
chemical mutants were assayed at 15 µM for their ability to polymerize the reaction, which 
was monitored by OD at 340 nM using a CLARIOstar Plus plate reader (BMG Labtech). 
 
5.14 Sanger sequencing  
 
All DNA sequences were analysed by the laboratory of John Lester in the DNA 
sequencing facility at the Department of Biochemistry (University of Cambridge). All 
sequencing was performed using a T7 primer for the antibody mutants and a T7-rev primer for 
the Tau mutants. Sequencing data was analysed using A Plasmid Editor software.  
 
5.15 NanoDrop 2000  
 
All DNA and protein concentrations and quality were measured at 260/280 nm 







Confirmation of all protein sizes was carried out using pre-cast Novex® NuPAGE® 
SDS-PAGE gels (Thermo Scientific) with the appropriate standard protein ladders and using 
NuPAGE® MES SDS running buffer (20x, Thermo Scientific). Electrophoresis was performed 
at constant voltage 200V for 35 minutes. Photos were taken and analysed using GelDocXR 
software. 
 
5.17 Common solution recipes  
 
PBS: 1x PBS tablet (Gibco) per 500 mL ddmQ H2O to yield 10 mM Phosphate, 140 mM NaCl, 
2.7 mM KCl, pH 7.4. 
 
LB-Media: 1% (w/v) Tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, pH 7.0. All LB-
media was autoclaved at 121 ºC for 15 minutes. 
 
TB-Media: 47.6 g of Terrific broth powder (Sigma Aldrich) was combined with 8 mL of 
glycerol in 1 L of distilled water. All TB-media was autoclaved at 121 ºC for 15 minutes. 
 
LB-Agar: 1.5% Agar (w/v) in LB-media, pH 7.0. All LB-Agar was autoclaved at 121 ºC for 15 
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